In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.

Back to Metastatic Trial Search
Powered by BreastCancerTrials.org
Profile: ER+/PR+

You have matched to trials (Last updated: April 17, 2021)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Genetics/Family History

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53


1

NEAREST SITE: 3 miles
University of California, San Francisco
San Francisco, CA

VISITS: Visits every 3 weeks, ongoing

PHASE: II

NCT ID: NCT03056755

Targeted Therapy Alpelisib and Anti-Estrogen Therapy for Advanced HR+, HER2- Breast Cancer with a PIK3CA Mutation

A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment Scientific Title

Purpose
To investigate the safety and effects (good and bad) of giving the PI3k inhibitor alpelisib (Piqray®) in combination with an anti-estrogen therapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer. Your tumor must test positive for a PIK3CA mutation and you must have already received a CDK4/6 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®), by mouth daily, ongoing</li> <li class="seamTextUnorderedListItem">Letrozole, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®) or leuprolide (Lupron®), by injection, monthly, ongoing (if you are a premenopausal woman or a man)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpelisib (Piqray®) is a PI3K inhibitor. </li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) and letrozole (Femara®) are the anti-estrogen (hormone) drugs used in this study.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03056755' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/conference-coverage/esmo-2018/alpelisib-combo-nearly-doubles-pfs-in-pik3camutant-breast-cancer' target='_blank'>OncLive: Alpelisib Combo Nearly Doubles PFS in PIK3CA</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.faslodex.com/what-is-faslodex.html' target='_blank'>AstraZeneca Drug Information Page: Faslodex® (Fulvestrant)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/aromatase_inhibitors' target='_blank'>Breastcancer.org: Aromatase Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/hormone-therapy/ovarian-suppression-breast-cancer' target='_blank'>Breast Cancer Now: Ovarian Suppression</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer-in-men/treating/hormone-therapy.html' target='_blank'>American Cancer Society: Hormone Therapy for Breast Cancer in Men</a> </li></ul>
See more
2

NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007)
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03742895

PARP Inhibitor Olaparib for Metastatic Breast Cancer That Tests Positive for a BRCA1/2 Tumor Mutation

A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer Scientific Title

Purpose
To study the safety and anti-cancer activity of using the PARP inhibitor Olaparib (Lynparza®) in cancer with a BRCA1/2 tumor mutation.
Who is this for?
People with metastatic (stage IV) breast cancer that tests positive for a BRCA1 or BRCA2 tumor (not inherited) mutation who have already recieved an anthracycline and a taxane-based chemotherapy. You may not enroll in this trial if you have an inherited BRCA1/2 mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice a day, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The PARP inhibitor being used in this study is olaparib (Lynparza®). It is approved to treat HER2-negative metastatic breast cancer in women with an inherited BRCA1/2 mutation.</li> <li class="seamTextUnorderedListItem">BRCA1/2 mutations can be inherited (also called germline) or in a tumor (also called somatic). </li> <li class="seamTextUnorderedListItem">This trial is only enrolling people with tumor BRCA1/2 mutations. </li> <li class="seamTextUnorderedListItem">PARP inhibitors work by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer that is BRCA1/2 tumor mutation positive.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1/2 tumor mutation</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03742895' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lynparza.com/results/metastatic-breast-cancer-results.html' target='_blank'>AstraZeneca Information Page: Lynparza® (Olaparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/parp-inhibitors-in-breast-cancer-treatment' target='_blank'>Breast Cancer Now: PARP Inhibitors in Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mygenecounsel.com/my-tumor-carries-a-brca-mutation/' target='_blank'>My Gene Counsel: A BRCA Mutation Was Found in My Tumor. Does This Mean I’m a BRCA Carrier?</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/parp-inhibitors-cancer/' target='_blank'>Metastatic Trial Talk: Get the Latest News on PARP Inhibitors</a> </li></ul>
See more
3

NEAREST SITE: 3 miles
University of California San Francisco (UCSF)
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03326102

Oral Paclitaxel in HER2- Recurrent and Metastatic Breast Cancer (OPERA)

A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer (OPERA) Scientific Title

Purpose
To compare the safety and effects (good and bad) of paclitaxel taken by mouth with paclitaxel that is given through a vein (IV).
Who is this for?
People with HER2-negative recurrent or metastatic (stage IV) breast cancer that has been treated with up to three lines of therapy other than a taxane.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups in a 2:1 ratio (twice as many participants will be in Group 1 as compared to Group 2): </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Paclitaxel by mouth</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">DHP107 by mouth, once a week, 3 weeks on/1 week off</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Paclitaxel by IV</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, once a week, 3 weeks on/1 week off</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The IV form of paclitaxel (Taxol®) is approved to treat metastatic breast cancer in the U.S.</li> <li class="seamTextUnorderedListItem">The oral form (DHP107) is approved to treat metastatic breast cancer in Korea. There it is sold as Liporaxel®.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03326102' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/paclitaxel' target='_blank'>Cancer Research UK: Paclitaxel</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1084' target='_blank'>Journal of Clinical Oncology: Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients</a> </li></ul>
See more
4

NEAREST SITE: 3 miles
California Pacific Medical Center-Pacific Campus
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT02465060

NCI-MATCH: Using Genomic Test Results To Choose A Targeted Therapy For Metastatic Breast Cancer

A Basket study: Molecular Analysis for Therapy Choice (MATCH) Scientific Title

Purpose
To study the anti-cancer activity of receiving a targeting therapy that was chosen based on the results of your tumor's genomic testing.
Who is this for?
People with metastatic (stage IV) breast cancer whose cancer progressed during or after standard of care treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Your tumor sample will be tested for genetic mutations (genomic testing)</li> <li class="seamTextUnorderedListItem">You will be assigned to 1 of 24 treatment groups based on the results of your tumor's genomic test</li> <li class="seamTextUnorderedListItem">End-of-treatment biopsy and collection of blood samples for research purposes (optional)</li> <li class="seamTextUnorderedListItem">This process may be repeated if your disease progresses</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Genomic testing looks at genetic mutations within your tumor.</li> <li class="seamTextUnorderedListItem">The drug you receive will be determined by the results of your tumor's genomic test. </li> <li class="seamTextUnorderedListItem">Your may receive one or more of the following drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Larotrectinib, Nivolumab, Osimertinib, Palbociclib (CDK inhibitor), Pertuzumab (anti-HER2), PI3K-beta Inhibitor GSK2636771, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab emtansine/T-DM1 (Kadcyla®) (antibody-drug conjugate (ADC)), Vismodegib</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">This type of study is called a basket trial. Basket trials enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ABL, ALK, BRAF, CDK4, CDK6, CSF-1R, EGFR, EGFR T790M, FGFR, FLT3, HER2 (ERBB2), KIT, MET, MEK, mTOR, NTRK fusions, PD-1, PDGFR, PI3K, PTCH1, PTEN loss, RET, ROS1, SMO, TRK, VEGFR, WEE1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02465060' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match' target='_blank'>National Cancer Institute Study Website: NCI-Match</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/nci-match-eay131' target='_blank'>ECOG-ACRIN Cancer Research Group: NCI-Match</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/diagnosis/genomic_assays' target='_blank'>Breastcancer.org: Tumor Genomic Assay Testing</a> </li></ul>
See more
5

NEAREST SITE: 3 miles
University of California, San Francisco
San Francisco, CA

VISITS: At least 1 visit per month for 6 months

PHASE: I

NCT ID: NCT03970382

Personalized Immunotherapy With or Without Opdivo for Metastatic Hormone Positive Breast Cancer

A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors Scientific Title

Purpose
To determine the safety and the effects (good or bad) of an experimental T-cell immunotherapy called neoTCR-P1 when it is given with or without nivolumab (Opdivo®).
Who is this for?
People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+) breast cancer that has been treated with at least one standard therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeoTCR-P1, one time </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeoTCR-P1, one time </li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), once a month, for 6 months</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">NeoTCR-P1 makes a patient's T-cells target a neoepitope (neoE) that is found on their cancer cells. </li> <li class="seamTextUnorderedListItem">Opdivo is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking a protein called PD-1 (programmed cell death 1). It has been approved to treat certain types of cancer. Its use in breast cancer is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03970382' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/798453' target='_blank'>NCI Drug Dictionary: gene-edited autologous neoantigen-targeted NeoTCR-P1 T cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/nivolumab' target='_blank'>NCI Drug Dictionary: Nivolumab</a> </li></ul>
See more
6

NEAREST SITE: 3 miles
Sutter Palo Alto Medical Foundation: San Francisco
San Francisco, CA

VISITS: Coincides with targeted therapy

PHASE: II

NCT ID: NCT02693535

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

A Basket Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of using a tumor's genetic alterations to select an FDA-approved targeted therapy for treatment.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer for whom there is no currently available therapy. You must have results from a genomic or immunohistochemistry test approved by TAPUR.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Participants will receive an FDA-approved targeted therapy that is chosen based on the tumor's genetic makeup.</p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The targeted therapy you receive will be selected based on your tumor's specific genetic profile.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">Your treatment may include one or more of the following: Abemaciclib, Afatinib, Crizotinib, Nivolumab, Ipilimumab, Olaparib, Palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab, Pertuzumab, Vemurafenib, Cobimetinib</li> <li class="seamTextUnorderedListItem">Targets or mutations: ALK, ATM, BRAF, BRAF V600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, HER2 (ERBB2), high mutational load and others, KIT, MET, MSI-H, mTOR, NRG1, PALB2, PDGFR, POLD1, POLE, RAF-1, RET, ROS1, TSC, VEGFR</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02693535' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.tapur.org/' target='_blank'>ASCO Study Website: TAPUR</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/conference-coverage/asco-2016/dr-edward-kim-on-ascos-tapur-trial' target='_blank'>OncLive: About TAPUR (video)</a> </li></ul>
See more
7

NEAREST SITE: 3 miles
University of California San Francisco
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03659136

Xentuzumab, Everolimus and Exemestane in Advanced HR Positive, HER2 Negative Breast Cancer

XENERA™-1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Post-menopausal Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease Scientific Title

Purpose
To compare the effects (good and bad) of the combination of xentuzamab, everolimus (Afinitor®), and exemestane (Aromasin®) to the combination everolimus (Afinitor®) and exemestane (Aromasin®).
Who is this for?
Postmenopausal women advanced (some stage III) or metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Xentuzumab, by IV</li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®), by mouth</li> <li class="seamTextUnorderedListItem">Exemestane (Aromasin®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by IV</li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®), by mouth</li> <li class="seamTextUnorderedListItem">Exemestane (Aromasin®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Xentuzumab is an investigational targeted therapy that blocks insulin-like growth factor (IGF). </li> <li class="seamTextUnorderedListItem">Studies suggest it may improve how cancer cells respond to chemotherapy. </li> <li class="seamTextUnorderedListItem">Aromasin is an anti-estrogen drug used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">Afinitor is a chemotherapy drug used to treat advanced HR positive HER2 negative breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03659136' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.webmd.com/drugs/2/drug-17764/exemestane-oral/details' target='_blank'>WebMD: Exemestane</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/everolimus' target='_blank'>Cancer Research UK: Everolimus (Afinitor®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/xentuzumab' target='_blank'>NCI Drug Dictionary: Xentuzumab</a> </li></ul>
See more
8

NEAREST SITE: 3 miles
University of California San Francisco
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03250676

H3B-6545 for Postmenopausal Women with ER+, HER2- Breast Cancer

A Phase I-II Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Scientific Title

Purpose
To determine the best dose, safety, and effects (good and bad) of an experimental anti-estrogen drug called H3B-6545.
Who is this for?
Postmenopausal women with advanced (some stage III) or metastatic (stage IV) breast cancer that is estrogen receptor positive and HER2 negative. Your cancer must have progressed on your most recent therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">H3B-6545, by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">H3B-6545 is the experimental anti-estrogen therapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03250676' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/77/13_Supplement/DDT01-04' target='_blank'>AACR Abstract: H3B-6545</a> </li></ul>
See more
9

NEAREST SITE: 3 miles
University of California at San Francisco
San Francisco, CA

VISITS: 1 visit every 3 weeks

PHASE: III

NCT ID: NCT03975647

Trastuzumab Emtansine/T-DM1 Alone or with Tucatinib for Advanced, HER2+ Breast Cancer

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer Scientific Title

Purpose
To compare the anti-cancer activity and side effects of giving of the anti-HER2 targeted therapy tucatinib (Tukysa®) and trastuzumab emtansine/T-DM1 (Kadcyla®) together to just giving trastuzumab emtansine/T-DM1 (Kadcyla®).
Who is this for?
People with locally advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have previously been treated with a taxane and trastuzumab (Herceptin®).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, twice daily </li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine/T-DM1 (Kadcyla®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, twice daily </li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine/T-DM1 (Kadcyla®), by IV, every 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is an anti-HER2-targeted therapy approved for use with certain other therapies. Its use in this trial is considered experimental. </li> <li class="seamTextUnorderedListItem">Trastuzumab emtansine/T-DM1 (Kadcyla®) is an antibody-drug conjugate (ADC). It uses an antibody -— the HER2-targeted therapy trastuzumab (Herceptin®) -— to deliver the chemotherapy drug DM1 directly to the cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03975647' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tukysahcp.com' target='_blank'>Seagen Information Page: Tukysa (Tucatinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/kadcyla' target='_blank'>Breastcancer.org: Kadcyla® (Trastuzumab emtansine/T-DM1)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/publications/oncology-live/2018/vol-19-no-24/tucatinib-shows-promise-in-patients-with-breast-cancer-and-brain-metastases' target='_blank'>OncLive: Tucatinib Shows Promise in Patients With Breast Cancer and Brain Metastases</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/news/tucatinib-shows-promise-phase-i-study-her2-positive-breast-cancer' target='_blank'>CancerNetwork:Tucatinib Shows Promise in Phase I Study of HER2-Positive Breast Cancer</a> </li></ul>
See more
10

NEAREST SITE: 3 miles
University of California at San Francisco
San Francisco, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: I

NCT ID: NCT01969643

SGN-LIV1A for Women With Advanced HER2 Negative Breast Cancer

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer Scientific Title

Purpose
To study the safety, best dose and anti-tumor activity of SGN-LIV1A--an experimental antibody-drug conjuate (ADC).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-LIV1A, by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of therapy that combines an antibody that targets cancer cells with a therapy that can kill cancer cells. </li> <li class="seamTextUnorderedListItem">Because the antibody only targets cancer cells, the ADC does not kill normal cells, making it less likely to cause side effects. </li> <li class="seamTextUnorderedListItem">SGN-LIV1A is an antibody-drug conjugate.</li> <li class="seamTextUnorderedListItem">Its antibody targets LIV-1 (SLC39A6), a protein that is expressed by most breast cancer cells, and it delivers an anti-cancer drug called monomethyl auristatin E.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01969643' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.seagen.com/science/pipeline/ladiratuzumab-vedotin' target='_blank'>Seagen Drug Information Page: Ladiratuzumab Vedotin (SGN-LIV1A)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/antibody-drug-conjugates/' target='_blank'>Metastatic Trial Talk: Getting to the Target, Antibody Drug Conjugates</a> </li></ul>
See more
11

NEAREST SITE: 3 miles
UCSF Cancer Center
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03781063

Lasofoxifene or Fulvestrant in Advanced ER+, HER2- Breast Cancer with a ESR1 Mutation

An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation Scientific Title

Purpose
To compare the safety and effects (good and bad) of lasofoxifene (Fablyn®) to fulvestrant (Faslodex®).
Who is this for?
Postmenopausal women with advanced (stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received an aromatase inhibitor combined with a CDK 4/6 inhibitor, and have had a cell-free circulating tumor DNA (cDNA) test that shows your tumor has an ESR1 mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lasofoxifene (Fablyn®), by mouth, daily </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, once a month</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fablyn is a nonsteroidal selective estrogen receptor modulator (SERM). </li> <li class="seamTextUnorderedListItem">It has been approved for use in other countries to treat osteoporosis, but is not approved in the U.S. </li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03781063' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/hormone-therapy/fulvestrant-faslodex' target='_blank'>BreastCancerCare.org.uk: Fulvestrant (Faslodex)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.practiceupdate.com/content/lasofoxifene-vs-fulvestrant-for-hr-positive-breast-cancer/77342' target='_blank'>PracticeUpdate: Lasofoxifene vs Fulvestrant for HR-Positive Breast Cancer</a> </li></ul>
See more
12

NEAREST SITE: 3 miles
Research Site
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT04305496

Capivasertib & Fulvestrant or Fulvestrant Alone In Advanced ER+, HER2- Breast Cancer

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2−) Breast Cancer Following Recurrence or Progression On or After ... Scientific Title

Purpose
To compare the anti-cancer activity of giving the targeted therapy capivasertib in combination with the anti-hormone therapy fulvestrant to giving fulvestrant alone.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer. You must have already been treated with an aromatase inhibitor and you must not have received more than one chemotherapy and two hormone therapies for advanced or metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, twice the first month, then once a month, ongoing </li> <li class="seamTextUnorderedListItem">Capivasertib, by mouth, twice a day, 4 days a week, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, twice the first month, then once a month, ongoing </li> <li class="seamTextUnorderedListItem">Placebo, by mouth, twice a day, 4 days a week, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedure for premenopausal women</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A drug that will put you into menopause, by injection, monthly, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is an anti-hormone therapy that is commonly used to treat postmenopausal women with HR+ tumors that have stopped responding to other anti-hormonal therapies.</li> <li class="seamTextUnorderedListItem">Capivasertib is a targeted therapy that blocks the Akt protein. The Akt protein helps cancer cells divide and grow.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04305496' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/akt-inhibitor-azd5363' target='_blank'>NCI Drug Dictionary: Capivasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-fulvestrant-breast-cancer' target='_blank'>NCI Cancer Currents Blog: Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/conference-coverage/asco-2019/capivasertib-combined-with-fulvestrant-improves-pfs-in-er-breast-cancer' target='_blank'>OncLive: Capivasertib Combined With Fulvestrant Improves PFS in ER+ Breast Cancer</a> </li></ul>
See more
13

NEAREST SITE: 3 miles
UCSF
San Francisco, CA

VISITS: Coincides with standard of care

PHASE: III

NCT ID: NCT02947685

Anti-HER2 Targeted Therapy, Hormone Therapy, and Palbociclib for Metastatic HR+, HER2+ Breast Cancer

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer (PATINA) Scientific Title

Purpose
To compare the safety and effects (good and bad) of giving a CDK4/6 inhibitor with the standard of care therapies to the standard of care therapies alone.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 positive (HER2+) breast cancer. You must have already had at least 4 but no more than 8 cycles of a HER2 targeted therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily</li> <li class="seamTextUnorderedListItem">standard anti-HER2 therapy and hormone therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">standard anti-HER2 therapy and hormone therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a type of targeted therapy called a CDK4/6 inhibitor. It is approved for treating metastatic hormone positive, HER2 negative breast cancer. </li> <li class="seamTextUnorderedListItem">The standard of care for metastatic hormone positive, HER2 negative breast cancer is a combination of a HER2-targeted therapy and an anti-estrogen drug.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02947685' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Palbociclib' target='_blank'>Wikipedia: Palbociclib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ibrance.com' target='_blank'>Pfizer Oncology Drug Information Page: Ibrance</a> </li></ul>
See more
14

NEAREST SITE: 3 miles
UCSF Helen Diller Family CCC
San Francisco, CA

VISITS: 1-2 visits a month, ongoing

PHASE: I-II

NCT ID: NCT03280563

Immunotherapies, Targeted Therapies, and Anti-Estrogen Therapies for Advanced Hormone Positive, HER2 Negative Breast Cancer

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer) Scientific Title

Purpose
To evaluate the safety, effects (good and bad), and anti-cancer activity of several therapy combinations that include immunotherapies, targeted therapies, and anti-estrogen therapies.
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (ER+, HER2-) breast cancer. Your cancer must have recurred or progressed on your most recent treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 7 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, once a month, ongoing</li> <li class="seamTextUnorderedListItem">Entinostat, by mouth, once a week, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 5</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068), by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 6</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) by injection or tamoxifen (Nolvadex®) or exemestane (Aromasin®) by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 7</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, twice a month, ongoing</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, twice a day, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 1-2 times a month, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">If your disease progresses while on treatment, you may be eligible to receive a new combination treatment.</i> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsies may be required</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 checkpoint inhibitor. It is approved to treat locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.</li> <li class="seamTextUnorderedListItem">Entinostat is an investigational type of targeted therapy called an HDAC inhibitor.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">Ipatasertib (GDC-0068) is a new type of cancer drug that works by blocking the Akt protein</li> <li class="seamTextUnorderedListItem">Bevacizumab (Avastin) is a monoclonal antibody that keeps tumors from growing by shrinking their supplying blood vessels. Avastin is used to treat HER2-negative metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03280563' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.biooncology.com/pipeline-molecules/ipatasertib.html' target='_blank'>Genentech Drug Information Page: Ipatasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.gene.com/patients/medicines/tecentriq' target='_blank'>Genentech Drug Information Page: Tecentriq</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/hormone-therapy/fulvestrant-faslodex' target='_blank'>Breast Cancer Now: Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/entinostat' target='_blank'>NCI Drug Dictionary: Entinostat</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/avastin' target='_blank'>Breastcancer.org: Avastin</a> </li></ul>
See more
15

NEAREST SITE: 3 miles
University of California, San Francisco Medical Center
San Francisco, CA

VISITS: 1 visit every 4 weeks, ongoing

PHASE: II

NCT ID: NCT01494662

Neratinib for People With HER2 Positive Brain Metastases

A Phase II Trial of HKI-272 (Neratinib) for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases Scientific Title

Purpose
To determine how well neratinib (Nerlynx®) works in treating breast cancer that has spread to the brain, as well as the effect that it has on cognitive functioning.
Who is this for?
People with metastatic (stage IV), HER2 positive (HER2+) breast cancer that has spread to the brain.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®), by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases are difficult to treat because many drugs are unable to cross the blood-brain barrier, which means they cannot enter the brain from the bloodstream. </li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is a tyrosine kinase inhibitor approved for use in treating metastatic HER2 positive breast cancer in combination with capecitabine.</li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) works by blocking the HER2 and EGFR receptors, both of which are involved in cancer cell growth. </li> <li class="seamTextUnorderedListItem">Neratinib (Nerlynx®) is a much smaller molecule than Herceptin® (the drug widely used to treat HER2+ tumors), and it is able to cross the blood-brain barrier. </li> <li class="seamTextUnorderedListItem">The goal of this trial is to determine how well it works in treating breast cancer that has spread to the brain, as well as the effect that it has on cognitive functioning.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01494662' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/neratinibmaleate' target='_blank'>NCI Drug Dictionary: Neratinib</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Mets Frequently Asked Questions</a> </li><li class='seamTextUnorderedListItem'><a href='https://externalmediasite.partners.org/Mediasite/Play/dbc4bfbf0f6a46208443613881b188e41d' target='_blank'>Dana-Farber Cancer Institute: Study Information Video</a> </li></ul>
See more
16

NEAREST SITE: 3 miles
University of California, San Francisco
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03554044

Imlygic With Taxol or Hormone Therapy for Advanced HER2 Negative Breast Cancer

A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Paclitaxel or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-Negative Breast Cancer With Evidence of Injectable Disease in the Locoregional Area Scientific Title

Purpose
To study the safety, anti-tumor activity and effects (good and bad) of combining talimogene laherparepvec (Imlygic®) with paclitaxel (Taxol®) or a hormone therapy of their doctor's choice.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Estrogen receptor negative</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talimogene laherparepvec (Imlygic®), by injection, every 2 weeks for 3 months, then every 3 weeks</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, every week</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Estrogen receptor positive</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talimogene laherparepvec (Imlygic®), by injection, every 2 weeks for 3 months, then every 3 weeks</li> <li class="seamTextUnorderedListItem">Hormone therapy (doctor's choice)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talimogene laherparepvec (Imlygic®) is an immunotherapy approved to treat advanced melanoma. It is injected directly into a tumor site. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug used to treat advanced breast cancer. </li> <li class="seamTextUnorderedListItem">Paclitaxel will be used with Imylgic® to treat estrogen receptor negative (ER-) patients. </li> <li class="seamTextUnorderedListItem">Study participants with estrogen receptor positive (ER+) tumors will be treated with Imylgic® and a hormone therapy selected by their doctor.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03554044' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/talimogene-laherparepvec' target='_blank'>NCI Dictionary of Cancer Terms: Talimogene Laherparepvec</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/breast-cancer/adding-oncolytic-virus-neoadjuvant-chemo-triple-negative-breast-cancer' target='_blank'>Cancer Network: Adding an Oncolytic Virus to Neoadjuvant Chemo for Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/paclitaxel-taxol' target='_blank'>Breast Cancer Now: Paclitaxel (Taxol®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/recur_metast/treat_metast/options/hormonal' target='_blank'>Breastcancer.org: Hormonal Therapy to Treat Metastatic Breast Cancer</a> </li></ul>
See more
17

NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

VISITS: Weekly visits for 2 months, monthly visits thereafter

PHASE: II

NCT ID: NCT03519178

PF-06873600 for Metastatic HER2-Negative Breast Cancer

Phase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of PF-06873600, a new targeted therapy.
Who is this for?
People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or hormone receptor (ER+ and/or PR+) positive, HER2 negative (HER2-) breast cancer who have already received a CDK 4/6 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-06873600, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-06873600, by mouth</li> <li class="seamTextUnorderedListItem">Endocrine therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PF-06873600 is a cyclin-dependent kinase (CDK) inhibitor. </li> <li class="seamTextUnorderedListItem">It works by inhibiting the CDK enzymes that help cancer cells grow. </li> <li class="seamTextUnorderedListItem">Patients in the study with hormone-receptor positive breast cancer will also be treated with an anti-estrogen therapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03519178' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793673' target='_blank'>NCI Drug Dictionary: PF-06873600</a> </li></ul>
See more
18

NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

VISITS: Visits every 3 weeks, ongoing

PHASE: II

NCT ID: NCT03095352

Keytruda plus Carboplatin to Treat Chest Wall Breast Cancer

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Scientific Title

Purpose
To compare the safety and effects (good and bad) of giving immunotherapy along with chemotherapy versus giving chemotherapy alone to treat breast cancer that has spread to the chest wall.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that has spread to the chest wall and cannot be removed by surgery.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Biopsies and blood samples before and after treatment </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard treatment</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks, ongoing </li> <li class="seamTextUnorderedListItem">Biopsies and blood samples before and after treatment</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is the immunotherapy drug used in this study. It is a PDL-1 inhibitor approved to treat certain types of cancers. </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®) is the chemotherapy drug used in this study.</li> <li class="seamTextUnorderedListItem">In this trial, researchers will test tumor biopsies and blood samples before and after treatment in order to learn more about how genes and the immune system affect how tumors respond to immunotherapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03095352' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS1113' target='_blank'>ASCO Abstract: Pembrolizumab and Carboplatin</a> </li></ul>
See more
19

NEAREST SITE: 3 miles
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04171700

PARP Inhibitor Rucaparib in Advanced Breast Cancer that is BRCA+ (Inherited or Tumor) or Tests Positive for Other Mutations

A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes (LODESTAR) Scientific Title

Purpose
To look at the safety, effects (good and bad), and anti-tumor activity of the PARP inhibitor rucaparib (Rubraca®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have been treated with at least one standard of care therapy but no more than two lines of chemotherapy; and who have inherited (or whose tumor tests positive for) one of the several mutations listed below.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rucaparib (Rubraca®), by mouth, twice a day, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rucaparib (Rubraca®) is a PARP inhibitor: it blocks poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA. It is approved to treat women with advanced ovarian cancer whose tumors have a BCRA 1 or BRCA 2 mutation. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">People with an inherited BRCA 1 or BRCA 2 mutation and whose tumor is HER2 negative (HER2-) tumor are not eligible for this trial. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of advanced cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1 (tumor or inherited), BRCA2 (tumor or inherited), PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04171700' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.rubraca.com/?utm_source=google&utm_medium=cpc&utm_term=rucaparib&utm_campaign=Branded_Alone_GS_EX&gclid=Cj0KCQiAsbrxBRDpARIsAAnnz_OQBEzA3MVbEPTW02l-js4vH6_2yBSOiLDwbWxO914whM6BmwDeWMsaAse7EALw_wcB' target='_blank'>Drug Company Information Page: Rubraca® (Rucaparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2019/02/04/mbc-news-8/' target='_blank'>Metastatic Trial Talk: Get the Latest News on PARP Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncologypro.esmo.org/oncology-in-practice/anti-cancer-agents-and-biological-therapy/parp-inhibition-and-dna-damage-response-ddr/parp-inhibitors/clinical-activity/breast-cancer/ongoing-developments' target='_blank'>ESMO Oncology: PARP Inhibitors in Breast Cancer (HRR Gene Mutations)</a> </li></ul>
See more
20

NEAREST SITE: 3 miles
Kaiser Permanente-San Francisco
San Francisco, CA

VISITS: Weekly visits for 3-6 months; then 1 visit every 3 weeks, ongoing

PHASE: III

NCT ID: NCT03199885

Paclitaxel, Trastuzumab, & Pertuzumab With or Without Atezolizumab For Metastatic HER2+ Breast Cancer

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Scientific Title

Purpose
To compare the safety and effects of the combination of pertuzumab (Perjeta®), trastuzumab (Herceptin®), paclitaxel (Taxol®), and atezolizumab (Tecentriq®) with the combination of pertuzumab (Perjeta®), trastuzumab (Herceptin®), paclitaxel (Taxol®), and a placebo.
Who is this for?
People who are starting treatment for metastatic (stage IV) breast cancer or have had their breast cancer recur after 6 months of neoadjuvant or adjuvant HER2-targeted therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pertuzumab, (Perjeta®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, for 3-6 months</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV, every 3 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pertuzumab, (Perjeta®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, for 3-6 months</li> <li class="seamTextUnorderedListItem">Placebo, by IV, every 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®) and trastuzumab (Herceptin®) are HER2-targeted therapies used to treat HER2 positive (HER2+) breast cancer. </li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat breast cancer.</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®) is a type of immunotherapy called a PD-L1 inhibitor.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03199885' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.gene.com/patients/medicines/tecentriq' target='_blank'>Genentech Information Page: Tecentriq</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/perjeta' target='_blank'>Breastcancer.org: Perjeta® (Pertuzumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.html' target='_blank'>American Cancer Society: Targeted Therapy for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/Taxol.aspx' target='_blank'>Chemocare: Taxol</a> </li></ul>
See more
21

NEAREST SITE: 3 miles
University of California San Francisco Medical Center
San Francisco, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: I

NCT ID: NCT04042701

Trastuzumab Deruxtecan and Pembrolizumab for Advanced HER2 Positive and HER2 Low Expression Breast Cancer

A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, In Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC) Scientific Title

Purpose
To find the best dose and to study the safety, effects (good and bad), and anti-tumor activity of the targeted therapy fam-trastuzumab deruxtecan-nxki (Enhertu®) when it is given in combination with the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 low expression breast cancer whose cancer progressed after receiving trastuzumab emtansine/T-DM1 (Kadcyla®) or standard of care therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fam-Trastuzumab Deruxtecan-nxki (Enhertu®), by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 low expression is defined as IHC 1+ or 2+ and ISH-.</li> <li class="seamTextUnorderedListItem">Fam-Trastuzumab Deruxtecan-nxki (Enhertu®) is an antibody-drug conjugate (ADC). It targets HER2 to deliver a chemotherapy drug directly to the cancer cells. It is approved for use to treat people with metastatic HER2+ breast cancer who have already received two anti-HER2 therapies. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor.</li> <li class="seamTextUnorderedListItem">Blocking PD-1 allows the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of solid tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04042701' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer' target='_blank'>FDA: FDA Approves Fam-Trastuzumab Deruxtecan-nxki</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/fam-trastuzumab-deruxtecan' target='_blank'>NCI Drug Dictionary: Fam-Trastuzumab Deruxtecan</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopost.com/news/february-2020/trastuzumab-deruxtecan-in-her2-low-expressing-previously-treated-advanced-breast-cancer/' target='_blank'>ASCO Post: Trastuzumab Deruxtecan in HER2–Low-Expressing, Previously Treated Advanced Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Pembrolizumab' target='_blank'>Wikipedia: Pembrolizumab</a> </li></ul>
See more
22

NEAREST SITE: 8 miles
Bay Area Breast Surgeons Inc
Emeryville, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT03994796

Genetic Testing for Choosing a Targeted Therapy for Brain Metastases that Test Positive for Certain Mutations

Genomically-Guided Treatment Trial in Brain Metastases Scientific Title

Purpose
To study the anti-cancer activity of choosing a targeted therapy for brain metastases based on the genetic mutations found in your tumors.
Who is this for?
People with metastatic (stage IV) breast cancer that has spread (metastasized) to your brain with a gene mutation or alteration in: NTRK, ROS1, CDK or PI3K. You must have already received at least one treatment for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups depending on which genetic mutations are found in your tumors: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: CDK-mutation</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, twice a day, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: PI3K-mutation</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-0084, by mouth, daily, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: NTRK or ROS1-mutation</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Entrectinib (Rozlytrek®), by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor samples from your brain and other parts of your body will be tested for mutations. This is called genomic testing.</li> <li class="seamTextUnorderedListItem">You will be assigned a targeted therapy based on which genetic mutations are found in your tumors.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer. </li> <li class="seamTextUnorderedListItem">Targets or mutations: NTRK, ROS1, CDK, PI3K</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03994796' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Mets</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verzenio.com/hcp/patient-profiles' target='_blank'>Eli Lilly & Company Drug Information Page: Verzenio® (Abemaciclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.rozlytrek.com' target='_blank'>Genentech USA Drug Information Page: Rozlytrek (Entrectinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-inhibitor-gdc-0084' target='_blank'>NCI Drug Dictionary: GDC-0084</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancernetwork.com/view/targeting-sanctuary-site-options-when-breast-cancer-metastasizes-brain' target='_blank'>Journal Article: Targeting the Sanctuary Site, Options when Breast Cancer Metastasizes to the Brain</a> </li></ul>
See more
23

NEAREST SITE: 22 miles
Contra Costa Regional Medical Center
Martinez, CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT03418961

Carvedilol to Prevent Heart Problems in Patients with Metastatic HER2+ Breast Cancer

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III Scientific Title

Purpose
To investigate whether giving people with HER2+ breast cancer a beta-blocker can help prevent heart problems caused by cancer treatments.
Who is this for?
People with HER2 positive metastatic (stage IV) breast cancer who are starting or continuing a trastuzumab-based anitHER2 therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Intervention</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carvedilol, by mouth, daily for up to 2 years</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No intervention</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: If you are already taking taking a beta blocker, ARB, or ACE inhibitor</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Observation for up to 2 years</li></ul>
  • <p class="seamTextPara"> The beta-blocker being used in this study is carvedilol. It is used to treat heart failure and high blood pressure.</p>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03418961' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/treatment/side_effects/heart_probs' target='_blank'>Breastcancer.org: Heart Problems</a> </li></ul>
See more
24

NEAREST SITE: 27 miles
Stanford University Hospitals and Clinics
Stanford, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT02401347

Talazoparib for Advanced HER2 Negative Breast Cancer with Certain Mutations

A Phase II Clinical Trial of BMN 673 in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency as Assessed by the HRD Assay, and (ii) Advanced HER2-Negative Breast Cancer With Either a Germline or Somatic Mutation in... Scientific Title

Purpose
To study the safety and anti-cancer activity of the PARP inhibitor talazoparib (Talzenna®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that is HER2 negative (HER2-) and who have received at least one prior chemotherapy for metastatic disease. Your tumor must test positive for or express one of several markers. (See below for a list of targets and mutations.) You cannot enroll in this trial if you have an inherited BRCA 1 or BRCA 2 mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®) is a PARP inhibitor that is approved to treat people with advanced or metastatic HER2 negative (HER2-) breast cancer and an inherited BRCA 1 or BRCA 2 mutation. </li> <li class="seamTextUnorderedListItem">You cannot enroll in this trial If you have an inherited BRCA 1 or BRCA 2 mutation.</li> <li class="seamTextUnorderedListItem">Targets or mutations: Homologous Recombination Deficiency, PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, Rad51c, Rad51d, MRE11, ATR, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCL, plus other HR-related genes at the discretion of the primary investigators.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02401347' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/EmergingMetasticBreastCancer.html' target='_blank'>Susan G. Komen: Emerging Areas in Metastatic Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com' target='_blank'>Pfizer Oncology Information Page: Talazoparib</a> </li></ul>
See more
25

NEAREST SITE: 28 miles
Stanford Cancer Center
Stanford, CA

VISITS: At least 1 visit every 2 months for the first year, then every 3 months thereafter

PHASE: I-II

NCT ID: NCT03215511

LOXO-195 for Advanced Breast Cancer with a NTRK Mutation

A Phase 1/ 2 Study of the TRK Inhibitor LOXO 195 in Adult Subjects With NTRK Fusion (Previously Treated) or Non-Fusion NTRK Altered Cancers Scientific Title

Purpose
To test the safety and effects (good and bad) of LOXO-195.
Who is this for?
People with locally advanced (stage III) or metastatic (stage IV) breast cancer that has an NTRK mutation. You must have no other standard treatment options available and have previously received a TRK inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-195, by mouth</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LOXO-195 is an investigational drug. </li> <li class="seamTextUnorderedListItem">It is a tyrosine-kinase inhibitor that binds to the TRK protein. </li> <li class="seamTextUnorderedListItem">Researchers believe it can stop cancer cell growth in tumors with an NTRK mutation.</li> <li class="seamTextUnorderedListItem">Targets or mutations: NTRK</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03215511' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trk-inhibitor-loxo-195' target='_blank'>NCI Dictionary: LOXO-195</a> </li></ul>
See more
26

NEAREST SITE: 28 miles
Stanford Cancer Center
Palo Alto, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04106492

Experimental Therapy SQ3370 for Advanced Breast Cancer

A Multicenter Phase 1, Open-Label Study of SQ3370 in Patients With Advanced Solid Tumors Scientific Title

Purpose
To study the safety, dose, side effects and anti-cancer activity of the experimental therapy SQ3370.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SQL70, by injection into your tumor</li> </ul> <p class="seamTextPara"> followed by </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SQP33, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receiving SQ3370 is a 2-step process because it is made of two different therapies that are given separately.</li> <li class="seamTextUnorderedListItem">First you receive therapy SQL70 by injection directly into the area near your tumor. Then you receive therapy SQP33 by IV.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04106492' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e15525' target='_blank'>ASCO Abstract: Effect of Local Activation via SQ3370 on the Safety of Chemotherapy with Concomitant Anti-Tumor Immune Response</a> </li></ul>
See more
27

NEAREST SITE: 28 miles
Kaiser Permanente - Northern California
Vallejo, CA

VISITS: Please contact research site

PHASE: NA

NCT ID: NCT03061305

Molecular Profiling to Select Treatment for Advanced Breast Cancer

Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection (STRATA) Scientific Title

Purpose
To conduct a test of your tumor to determine if there are approved therapies or clinical trials targeting the mutations or biomarkers found in your tumor.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> Molecular profiling will be done on your tumor sample at no cost.</p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A sample of your tumor will be tested for certain mutations and biomarkers. </li> <li class="seamTextUnorderedListItem">Your doctor will be told if there are treatments or clinical trials available for people with the mutations or biomarkers found in your tumor. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling patients with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: EGFR, BRAF, ERBB2 (HER2), and ALK</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03061305' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/broad-molecular-profiling-tests' target='_blank'>Breastcancer.org: Broad Molecular Profiling Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://unclineberger.org/research/octr/our-research/strata-trial' target='_blank'>UNC Lineberger Comprehensive Cancer Center: Study website</a> </li></ul>
See more
28

NEAREST SITE: 28 miles
Stanford University School of Medicine
Palo Alto, CA

VISITS: 1 visit every 2 weeks, ongoing

PHASE: I

NCT ID: NCT03821233

ZW49 in Patients With Advanced HER2-Positive Breast Cancer

A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers Scientific Title

Purpose
To evaluate the safety, effects (good and bad), and best dose of a new targeted therapy called ZW49.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZW49, by IV, every 2 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZW49 uses an antibody that can attach to HER2 proteins to deliver chemotherapy directly to the cancer cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of HER2 positive tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03821233' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zymeworks.com/our-pipeline/zw49' target='_blank'>Drug Company Study Information: ZW49</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/78/13_Supplement/3914' target='_blank'>AACR Journal Abstract: ZW49, A HER2-Targeted Biparatopic Antibody-Drug Conjugate for the Treatment of HER2-expressing Cancers</a> </li></ul>
See more
29

NEAREST SITE: 28 miles
Stanford University
Stanford, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04504331

Infigratinib and Tamoxifen for Advanced, HR+, HER2- Breast Cancer with a FGFR Alteration

A Phase 1B Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Scientific Title

Purpose
To study the best dose, side effects, and anti-cancer activity of infigratinib when it is given in combination with the anti-estrogen therapy tamoxifen.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Infigratinib, by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex®), by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tamoxifen (Nolvadex ®) is an anti-estrogen therapy commonly used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">Infigratinib is an experimental kinase inhibitor, a type of targeted therapy, that is designed to block the FGFR (fibroblast growth factor receptor) protein.</li> <li class="seamTextUnorderedListItem">Research suggests that targeting FGFR may slow or stop cancer cell growth.</li> <li class="seamTextUnorderedListItem">Targets or mutations: FGFR</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04504331' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.qedtx.com/discover-infigratinib/' target='_blank'>QED Therapeutics Drug Information Page: Infigratinib</a> </li><li class='seamTextUnorderedListItem'><a href='http://targetedcancercare.massgeneral.org/My-Trial-Guide/Diseases/Breast-Cancer/FGFR-1,-2,-3-and-4.aspx' target='_blank'>MGH Cancer Center: Breast Cancer, FGFR</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sciencedirect.com/science/article/abs/pii/S0960977617306094' target='_blank'>Journal Article: Targeting FGFR Pathway in Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/hormonal/serms/tamoxifen' target='_blank'>Breastcancer.org: Tamoxifen</a> </li></ul>
See more
30

NEAREST SITE: 28 miles
Stanford University
Palo Alto, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT04278144

BDC-1001 With or Without Keytruda for People With Advanced HER2 Positive Breast Cancer

Phase 1 Study of BDC-1001 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced and HER2-Expressing Solid Tumors Scientific Title

Purpose
To study the anti-cancer activity and effects (good and bad) of giving the new immunotherapy drug BDC-1001 alone and with the PD-1 inhibitor pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have no other treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> This is a 2-part study. Depending upon which part of the trial is open when you enroll, you will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Part 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BDC-1001</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Part 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BDC-1001</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BDC-1001 is an investigational drug called an Immune Stimulating Antibody Conjugate. It combines an anti-HER2 drug with a drug that targets the TLR7/8 proteins. </li> <li class="seamTextUnorderedListItem">Researchers think targeting the TLR7/8 proteins can help make tumors more likely to respond to pembrolizumab (Keytruda®). </li> <li class="seamTextUnorderedListItem">Pembrolizumab is another type of immunotherapy called a PD-1 inhibitor. It works by getting the immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04278144' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://boltbio.com/#ourscience' target='_blank'>Drug Company Information Page: BDC-1001</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytru' target='_blank'>Merck Oncology: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nationalbreastcancer.org/breast-cancer-targeted-therapy' target='_blank'>National Breast Cancer Foundation: Targeted Therapy (Monoclonal Antibodies)</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Immune_stimulating_antibody_conjugate' target='_blank'>Wikipedia: Immune Stimulating Antibody Conjugate</a> </li></ul>
See more
31

NEAREST SITE: 53 miles
St. Joseph Heritage Healthcare
Santa Rosa, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03251378

Targeted Therapy Fruquintinib for Metastatic HER2 Negative Breast Cancer

A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors Scientific Title

Purpose
To study the safety and effects (good and bad) of the experimental targeted therapy fruquintinib.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer who have not already received a VEGFR inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fruquintinib, by mouth, daily (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fruquintinib is a tyrosine kinase inhibitor, a type of targeted therapy, that is designed to block the VEGFR (vascular endothelial growth factor receptor) protein.</li> <li class="seamTextUnorderedListItem">Tumors use VEGFR to grow new blood vessels and research suggests VEGFR inhibitors may slow or stop cancer cell growth. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03251378' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.vicc.org/clinical-trials/protocol-viccgip1965' target='_blank'>Vanderbilt-Ingram Cancer Center Study Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fruquintinib' target='_blank'>NCI Drug Dictionary: Fruquintinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/VEGF_receptor' target='_blank'>Wikipedia: VEGF Receptor</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drugs.com/drug-class/vegf-vegfr-inhibitors.html' target='_blank'>Drugs.com: What are VEGF/VEGFR inhibitors?</a> </li></ul>
See more
32

NEAREST SITE: 53 miles
St. Joseph Health
Santa Rosa, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04432454

Lasofoxifene and Abemaciclib for Women with Advanced ER+, HER2- Breast Cancer with an ESR1 Mutation

An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII ) Scientific Title

Purpose
To study the safety, side effects, and anti-cancer activity of giving lasofoxifene (Fablyn®) and abemaciclib (Verzenio®) together.
Who is this for?
Women with locally advanced (some stage III) or metastatic (stage IV), hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have already received at least one hormone therapy and no more than one chemotherapy for metastatic disease and whose breast cancer tests positive for an ESR1 mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lasofoxifene (Fablyn®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, twice a day, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Lasofoxifene (Fablyn®) is a nonsteroidal selective estrogen receptor modulator (SERM), which is a type of anti-estrogen therapy. </li> <li class="seamTextUnorderedListItem">It has been approved for use in other countries to treat osteoporosis, but is not approved in the U.S. and its use in this trial is considered experimental. </li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ESR1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04432454' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oncnursingnews.com/web-exclusives/overcoming-ai-resistance-in-esr1mutant-breast-cancer' target='_blank'>Oncology Nursing News: Overcoming AI Resistance in ESR1-Mutant Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Abemaciclib' target='_blank'>Wikipedia: Abemaciclib</a> </li></ul>
See more
33

NEAREST SITE: 72 miles
Investigational Site Number 8400019
Woodland, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04059484

SAR439859 for Advanced ER+ Breast Cancer in Postmenopausal Women

An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopausal and Postmenopausal Patients With Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer With Prior Exposure to Hormonal Therapies Scientific Title

Purpose
To compare the anti-cancer activity and side effects of the experimental anti-estrogen drug SAR439859 with anti-estrogen drugs already approved and commonly used.
Who is this for?
Postmenopausal women with advanced (some stage III) or metastatic (stage IV) estrogen-receptor positive (ER+), HER2 negative (HER2-) breast cancer treated who have received no more than one chemotherapy or targeted therapy for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR439859, by mouth, daily, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Doctor's choice of anti-estrogen therapy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 biopsy</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR439859 is a type of anti-estrogen drug called a selective estrogen receptor degrader, or SERD.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04059484' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793484' target='_blank'>NCI Drug Dictionary: SAR439859</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/HormoneTherapies.html' target='_blank'>Susan G. Komen: Hormone Therapies for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader' target='_blank'>Wikipedia: SERD</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancerres.aacrjournals.org/content/78/13_Supplement/943' target='_blank'>Journal Abstract: SAR439859</a> </li><li class='seamTextUnorderedListItem'><a href='https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0620-6' target='_blank'>Journal Article: Overcoming Endocrine Resistance in Metastatic Hormone Receptor-positive Breast Cancer</a> </li></ul>
See more
34

NEAREST SITE: 74 miles
University of California Davis Comprehensive Cancer Center
Sacramento, CA

VISITS: 3 visits a month, ongoing

PHASE: II

NCT ID: NCT04090398

Paclitaxel Alone or With Radium-223 Dichloride For Metastatic HER2 Negative Breast Cancer With Bone Metastases

Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer Scientific Title

Purpose
To study the anti-cancer activity and effects (good and bad) of giving radium-223 dichloride (a type of radiation therapy given by IV) in combination with paclitaxel (Taxol®).
Who is this for?
People with metastatic (stage IV), HER2 negative (HER2-) breast cancer that has spread to the bone and who have not received more than three lines of chemotherapy for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Radium 223 dichloride (Xofigo®), by IV, once a month, for 6 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is a chemotherapy drug routinely used to treat metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Radium-223 dichloride (Xofigo®) is a radiation therapy given by IV. It works by killing cancer cells and may reduce the pain caused by bone metastases. </li> <li class="seamTextUnorderedListItem">Radium-223 dichloride (Xofigo®) is approved to treat metastatic prostate cancer that has spread to the bones. Its use in breast cancer is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04090398' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/oral-vs-iv-paclitaxel-for-mbc' target='_blank'>Breastcancer.org: Is Oral Paclitaxel Better Than IV Paclitaxel for Metastatic Breast Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/radium-223-dichloride.aspx' target='_blank'>Chemocare: Radium 223 Dichloride</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Radium-223' target='_blank'>Wikipedia: Radium-223</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/bone-mets/' target='_blank'>Metastatic Breast Cancer Network: Bone Mets</a> </li></ul>
See more
35

NEAREST SITE: 74 miles
University of California Davis Comprehensive Cancer Center
Sacramento, CA

VISITS: 1 visit every week, ongoing

PHASE: I-II

NCT ID: NCT03803761

Copanlisib and Fulvestrant for Metastatic Breast Cancer with a PIK3CA or PTEN Mutation

A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor Scientific Title

Purpose
To study the side effects and anti-cancer activity of giving copanlisib (Aliqopa®) in combination with fulvestrant (Faslodex®).
Who is this for?
Postmenopausal women with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have already received a CDK 4/6 inhibitor for metastatic disease and whose tumor tests positive for a PIK3CA or PTEN mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 2 times the first month, then once a month, ongoing</li> <li class="seamTextUnorderedListItem">Copanlisib (Aliqopa®), by IV, every week (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Copanlisib (Aliqopa®) is a type of targeted therapy called a PI3K inhibitor. It is approved for use in lymphoma, but its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is an anti-hormone therapy that is commonly used to treat postmenopausal women with HR+ tumors that have stopped responding to other anti-hormonal therapies.</li> <li class="seamTextUnorderedListItem">Testing for a PIK3CA or PTEN mutation may be done as part of the study.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA and PTEN</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03803761' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hcp.aliqopa-us.com/relapsed-follicular-lymphoma/?utm_source=google&utm_medium=cpc&utm_campaign=Aliqopa_Branded_HCP_%3BS%3BPH%3BBR%3BONC%3BHCP%3BBR&utm_content=Condition+-+Generic+-+Exact&utm_term=copanlisib+breast+cancer&matchtype=e&device=c&a' target='_blank'>Bayer Information Page: Aliqopa® (Copanlisib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-fulvestrant-breast-cancer' target='_blank'>NCI Cancer Currents Blog: Fulvestrant</a> </li></ul>
See more
36

NEAREST SITE: 74 miles
UC Davis Comprehensive Cancer Center
Sacramento, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04306900

TTX-030 in Combination With Chemotherapy or Immunotherapy or Both in Advanced Breast Cancer

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors Scientific Title

Purpose
To study the safety, effects (good and bad), and anti-cancer activity of using TTX-030 (an experimental drug that targets the tumor microenvironment) with either chemotherapy or Budigalimab (a type of immunotherapy) or both chemotherapy and Budigalimab.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 4 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TTX-030</li> <li class="seamTextUnorderedListItem">Budigalimab (ABBV-181), by IV</li> <li class="seamTextUnorderedListItem">mFOLFOX6, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TTX-030</li> <li class="seamTextUnorderedListItem">Budigalimab (ABBV-181), by IV</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TTX-030</li> <li class="seamTextUnorderedListItem">mFOLFOX6, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 4</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TTX-030</li> <li class="seamTextUnorderedListItem">Budigalimab (ABBV-181), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TTX-030 is an experimental drug that may work by changing the tumor microenvironment (the tissue that surrounds the tumor) and by causing the immune system to go after the tumor. </li> <li class="seamTextUnorderedListItem">Budigalimab (ABBV-181) is an experimental PD-1 inhibitor. PD-1 inhibitors are a type of immunotherapy that get the immune system to see and go after cancer cells.</li> <li class="seamTextUnorderedListItem">Docetaxel (Taxotere®) is a chemotherapy commonly used in breast cancer. </li> <li class="seamTextUnorderedListItem">mFOLFOX6 is a chemotherapy regimen that combines three different drugs: leucovorin calcium, fluorouracil, and, oxaliplatin. It is commonly used in colorectal cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04306900' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tizonatx.com/science/' target='_blank'>Drug Company Information Page: TTX-030</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd1-monoclonal-antibody-abbv-181' target='_blank'>NCI Drug Dictionary: Budigalimab (ABBV-181)</a> </li><li class='seamTextUnorderedListItem'><a href='https://abbviescience.com/oncology/pipeline' target='_blank'>Drug Company Information Page: ABBV-181 (Budigalimab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/folfox' target='_blank'>NCI Drug Dictionary: mFOLFOX-6</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/docetaxel.aspx' target='_blank'>Chemocare: Docetaxel</a> </li></ul>
See more
37

NEAREST SITE: 79 miles
University of California, Davis - Health Systems
Sacramento, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04148937

The Targeted Therapy LY3475070 Alone or With Pembrolizumab in Advanced Breast Cancer

A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies Scientific Title

Purpose
To study the safety, anti-cancer activity, and effects (good and bad) of the experimental targeted therapy LY3475070 when it is given alone or with the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) breast cancer who have no other standard treatment options.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3475070, by mouth, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3475070, by mouth, ongoing</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3475070 is a type of investigational therapy called a CD73 inhibitor. </li> <li class="seamTextUnorderedListItem">CD73 is a protein that may be a new biomarker in triple negative (ER-, PR-, HER2-) breast cancer. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking PD-1.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is approved to treat certain other types of cancers. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04148937' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lillytrialguide.com/en-US/studies/advanced-cancer/jzma' target='_blank'>Eli Lilly & Company Trial Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=pembrolizumab&utm_kxconfid=sq7irm3mh&gclid=CjwKCAiA1L_xBRA2EiwAgcLKA1rjY2sDvGijJBKlq4pryVynCh4LO-tR1STTRbK7a6-qFcn3XQre2RoC' target='_blank'>Merck Oncology: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='http://tcr.amegroups.com/article/view/21463/html' target='_blank'>Journal Article: CD73, A New Biomarker in Triple-negative Breast Cancer</a> </li></ul>
See more
38

NEAREST SITE: 158 miles
Local Institution
Fresno, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03471663

D-0502 Alone or in Combination With Palbociclib for Advanced ER+, HER2- Breast Cancer

A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer Scientific Title

Purpose
To study the safety, effects (good and bad) and best dose of an experimental anti-estrogen therapy when it is given alone or in combination with palbociclib (Ibrance®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">D-0502, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">D-0502, by mouth</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">D-0502 is the experimental anti-estrogen therapy used in this study.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is approved to treat hormone sensitive, HER2 negative breast cancer in combination with an anti-estrogen therapy in postmenopausal women. </li> <li class="seamTextUnorderedListItem">If you are premenopausal, you will also be given a therapy that will stop your ovaries from producing estrogen.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03471663' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/78/13_Supplement/5776' target='_blank'>AACR Abstract: D-0502</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/ibrance' target='_blank'>Breastcancer.org: Palbociclib (Ibrance®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ibrance.com/?src_code=IBRW10028851' target='_blank'>Pfizer Oncology Drug Information Page: Ibrance® (Palbociclib)</a> </li></ul>
See more
39

NEAREST SITE: 198 miles
Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo, CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03723928

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703) Scientific Title

Purpose
To study if blood tests that look for tumor markers are as good as or better than imaging with PET and/or CT scans (the current standard of care) to determine if a tumor is growing.
Who is this for?
People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to have first line treatment for metastatic disease or have started treatment within the past month, and have at least one elevated tumor marker.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), at least every 3 months, ongoing</li> <li class="seamTextUnorderedListItem">Tumor Marker Test, if ordered by your doctor</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Marker Tests, every 1 to 2 months, ongoing</li> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), only if need is shown by a Tumor Marker Test</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This imaging trial will compare using blood tests to PET/CT scans for monitoring tumor growth. </li> <li class="seamTextUnorderedListItem">The tumor markers that will be tested for in this study are CA 15-3, CA27.29, and CEA.</li> <li class="seamTextUnorderedListItem">The imaging tests will be those ordered by your doctor.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03723928' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/blood_marker' target='_blank'>Breastcancer.org: Blood Marker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/about-us/collaborations/top-five-list-oncology/choosing-wisely®-top-five-cancer-related-tests-procedures-and-treatments-many-patients-do-not-need/topic-4-follow-tumor-marker-tests-and-imaging-tests-people-treated-breast-cancer' target='_blank'>ASCO Cancer.net: Follow-up Tumor Marker Tests and Imaging Tests for People Treated for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet' target='_blank'>NCI: Tumor Markers</a> </li><li class='seamTextUnorderedListItem'><a href='https://ozarkscancerresearch.org/wp-content/uploads/2019/04/SWOG-S1703.pdf' target='_blank'>Cancer Research for the Ozarks: Trial Information Page</a> </li></ul>
See more
40

NEAREST SITE: 318 miles
City of Hope Antelope Valley
Lancaster, CA

VISITS: Every 3 weeks, ongoing

PHASE: II

NCT ID: NCT02778685

Femara, Palbociclib, & Pembrolizumab for Metastatic ER Positive, HER2 Negative Breast Cancer

Phase II Study of the Addition of MK-3475 (Pembrolizumab) to Letrozole and Palbociclib in Patients With Metastatic Estrogen Receptor Positive Breast Cancer Who Have Stable Disease But Are Not Responding to Letrozole and Palbociclib Scientific Title

Purpose
To study the anti-cancer activity and effects (good and bad) of adding the immunotherapy drug pembrolizumab (Keytruda®) to the commonly used combination of the anti-estrogen drug letrozole (Femara®) and the CDK 4/6 inhibitor palbociclib (Ibrance®).
Who is this for?
Women with metastatic (stage IV) estrogen receptor positive (ER+) HER2 negative (HER2-) breast cancer who have not yet started treatment.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Letrozole (Femara®) and palbociclib (Ibrance®) are an already approved therapy combination. </li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is an anti-estrogen therapy. </li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a CDK 4/6 inhibitor, which is a type of targeted therapy. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking the protein PD-1.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02778685' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Palbociclib' target='_blank'>Wikipedia: Palbociclib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ibrance.com' target='_blank'>Pfizer Oncology Drug Information Page: Ibrance® (Palbociclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com/?src=google&med=cpc&camp=Keytruda+Pan+Tumor_Brand_BRND_NA_ENGM_EXCT_TEXT_NA&adgrp=Brand+Keyword_General&kw=keytruda&utm_kxconfid=sq7irm3mh&gclid=CjwKCAjwycfkBRAFEiwAnLX5IZ2WUInCzwQ56GHMYYq-KXijoX1dzOK1O8HBbmaxajT0CPi2CbX3sRoC3A4QA' target='_blank'>Merck Oncology Drug Information Page: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/articles/the-evolving-field-of-erpositive-metastatic-breast-cancer-care' target='_blank'>Cure Today: The Evolving Field of ER Positive-Metastatic BC</a> </li></ul>
See more
41

NEAREST SITE: 330 miles
Synergy Hematology Oncology
Encino, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03382340

IMX-110 for Advanced Breast Cancer

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of IMX-110, an experimental targeted therapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IMX-110</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">IMX-110 is made up of a tyrosine kinase inhibitor that targets the Stat3 and NF-kB proteins and the chemotherapy drug doxorubicin. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of solid tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03382340' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nccn.org/patients/resources/life_with_cancer/treatment/targeted_therapy.aspx' target='_blank'>National Comprehensive Cancer Network: Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://emedicine.medscape.com/article/1947145-medication#9' target='_blank'>MedScape: Tyrosine Kinase Inhibitors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/22339066' target='_blank'>Journal Article Abstract: Doxorubicin-loaded Nanoparticles: New Advances in Breast Cancer Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='http://immixbio.com/pipeline/' target='_blank'>Drug Company Information Page: IMX-110</a> </li></ul>
See more
42

NEAREST SITE: 336 miles
University of California, Los Angeles Hematology/Oncology
Los Angeles, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04244552

ATRC-101 (An Experimental Immunotherapy) for Advanced Breast Cancer

A First-in-Human Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 in Adults With Advanced Solid Malignancies Scientific Title

Purpose
To study the safety and effects (good and bad) of the experimental immunotherapy ATRC-101.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATRC-101</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ATRC-101 is a new drug that is designed to get the immune system to see and attack cancer cells. </li> <li class="seamTextUnorderedListItem">It is also believed to change the microenvironment (the area that surrounds the cancer cells), which may make it easier for the immune cells to kill the cancer cells.</li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of solid cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04244552' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.atreca.com/pipeline/' target='_blank'>Drug Company Information Page: ATRC-101</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/immunotherapy.html' target='_blank'>American Cancer Society: Immunotherapy for Breast Cancer</a> </li></ul>
See more
43

NEAREST SITE: 336 miles
UCLA Department of Medicine - Hematology & Oncology
Los Angeles, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: II

NCT ID: NCT04539938

Tucatinib and Trastuzumab Deruxtecan for Advanced HER2 Positive Breast Cancer

A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer Scientific Title

Purpose
To study the anti-cancer activity and side-effects of giving tucatinib (Tukysa) in combination with fam-trastuzumab deruxtecan-nxki (Enhertu®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer. You must have already received at least two anti-HER2 targeted therapies for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa), by mouth, twice daily, ongoing</li> <li class="seamTextUnorderedListItem">Fam-Trastuzumab Deruxtecan-nxki (Enhertu®), by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa) is a type of HER2 targeting therapy called a kinase inhibitor. </li> <li class="seamTextUnorderedListItem">It is able to cross the blood-brain barrier. This means it works against cancer cells that have spread to the brain. </li> <li class="seamTextUnorderedListItem">Tucatinib is approved for use in people with metastatic, HER2+ breast cancer when it is taken with for use trastuzumab and capecitabine. Its use in this trial is considered experimental. </li> <li class="seamTextUnorderedListItem">Fam-trastuzumab deruxtecan-nxki (Enhertu®) is an antibody-drug conjugate (ADC). It targets HER2 to deliver a chemotherapy drug directly to the cancer cells. </li> <li class="seamTextUnorderedListItem">It is approved for use to treat people with metastatic HER2+ breast cancer who have already received two anti-HER2 therapies but its use in this trial is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04539938' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/tukysa' target='_blank'>Breastcancer.org: Tukysa</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/view/what-you-need-to-know-about-the-fdas-approval-of-tukysa-for-her2positive-breast-cancer' target='_blank'>Cure Today: What You Need to Know About the FDA's Approval of Tukysa for HER2 Positive Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.enhertuhcp.com/en/?utm_source=google&utm_medium=cpc&utm_campaign=branded+general_2020&utm_content=branded+general_2020_exact&utm_term=enhertu&gclid=cj0kcqjw8fr7brdsarisak0qqr5x8-k8j8h3d3_wahp-jhjvjjtjaqr3dnefidhs2onmte7b9gbmcfmaaoteealw_wcb&gc' target='_blank'>Daiichi-Sankyo AstraZeneca Drug Information Page: Enhertu®</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/brufsky-spotlights-data-with-trastuzumab-deruxtecan-in-her2-metastatic-breast-cancer' target='_blank'>OncLive: Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer</a> </li></ul>
See more
44

NEAREST SITE: 336 miles
UCLA Hematology-Oncology
Santa Monica, CA

VISITS: 1 visit every 3 or 4 weeks, ongoing

PHASE: I

NCT ID: NCT03255070

ARX788 for HER2 Positive Advanced Breast Cancer

A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression Scientific Title

Purpose
To evaluate the safety, effects (good and bad) and best dose of ARX788.
Who is this for?
People with HER2 positive advanced (some stage III) or metastatic (stage IV) breast cancer that has not responded to standard therapies and has already been treated with trastuzumab (Herceptin®).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ARX788, by IV, every 3 or 4 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ARX788 is an antibody-drug conjugate (ADC). </li> <li class="seamTextUnorderedListItem">It uses an antibody that targets HER2 positive cancer cells to deliver a chemotherapy drug called amberstatin269 directly to these cells. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03255070' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://ambrx.com/pipeline/arx788-aher2-adc-oncology/' target='_blank'>Drug Company Information Page: ARX788 HER2 ADC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-her2-antibody-drug-conjugate-arx788' target='_blank'>NCI Drug Dictionary: ARX788</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.hematologyandoncology.net/archives/april-2017/antibody-drug-conjugates-in-breast-cancer/' target='_blank'>Clinical Advances in Hematology & Oncology: ADC in Breast Cancer</a> </li></ul>
See more
45

NEAREST SITE: 336 miles
UCLA Hematology & Oncology Clinic
Los Angeles, CA

VISITS: 1 visit every 2-3 weeks

PHASE: I

NCT ID: NCT03219268

MGD013 With or Without Margetuximab for People With HER2 Positive Advanced Breast Cancer

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms Scientific Title

Purpose
To study the safety, effects (good and bad), and best dose of the immunotherapy MGD013 when used alone or in combination with the anti-HER2 targeted therapy margetuximab.
Who is this for?
People with HER2 positive (HER2+) advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> This is a 2-part study. Depending upon which part of the trial is open when you enroll, you will receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Part 1: All solid tumor cancers</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MGD013, by IV, every 2-3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Part 2: HER2 positive cancers only</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MGD013, by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Margetuximab, by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MGD013 is an investigational immunotherapy (only available in clinical trials) called a checkpoint inhibitor.</li> <li class="seamTextUnorderedListItem">MGD013 binds to the checkpoint inhibitors (proteins) PD-1 and LAG3, which helps your immune system go after cancer cells. </li> <li class="seamTextUnorderedListItem">Margetuximab is an investigational anti-HER2 targeted therapy. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced or metastatic solid tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03219268' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/792154' target='_blank'>NCI Drug Dictionary: MGD013</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.macrogenics.com/mgd013-pd-1-x-lag-3/' target='_blank'>Macrogenics Drug Information Page: MGD013</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Margetuximab' target='_blank'>Wikipedia: Margetuximab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immune-checkpoint-inhibitor' target='_blank'>NCI Dictionary of Cancer Terms: Immune Checkpoint Inhibitor</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nationalbreastcancer.org/breast-cancer-targeted-therapy' target='_blank'>National Breast Cancer Foundation: Targeted Therapy</a> </li></ul>
See more
46

NEAREST SITE: 338 miles
Sarcoma Oncology Center
Santa Monica, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT02568267

Basket Study of Entrectinib in Tumors With a NTRK1/2/3, ROS1, or ALK Mutation

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements Scientific Title

Purpose
To study the effects (good and bad) of entrectinib (Rozlytrek®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer. Your tumor must test positive for or express one of the following: NTRK 1/2/3, ROS 1, or ALK mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Entrectinib (Rozlytrek®), by mouth, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Basket studies enroll people based on the kind of mutations found in their tumors. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer whose tumors test positive for certain mutations.</li> <li class="seamTextUnorderedListItem">Targets or mutations: NTRK 1/2/3, ROS1, and ALK</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02568267' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.rozlytrek.com/?c=ent-16b05ae9ce6&gclid=Cj0KCQjw-_j1BRDkARIsAJcfmTHfl5vGlhgj7U1G_eLElm-4GOU_P5TcEhf6NBVhkZbfVZ07uc4f9UwaAnOiEALw_wcB&gclsrc=aw.ds' target='_blank'>Genentech Information Page: Rozlytrek® (Entrectinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Entrectinib' target='_blank'>Wikipedia: Entrectinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2019/fda-entrectinib-ntrk-fusion' target='_blank'>NCI Cancer Currents Blog: FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type</a> </li></ul>
See more
47

NEAREST SITE: 338 miles
Cancer Center of Southern California
Santa Monica, CA

VISITS: 1 visit every week, ongoing

PHASE: I

NCT ID: NCT03099174

Xentuzumab, Abemaciclib & an Anti-Estrogen Drug for Advanced Breast Cancer

An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts Scientific Title

Purpose
To study the best dose, safety, and anti-cancer activity of combining the CDK 4/6 inhibitor abemaciclib (Verzenio®) with xentuzumab and an anti-estrogen therapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV), hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received no more than two therapies for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Xentuzumab (BI 836845), by IV, weekly, ongoing</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Hormone therapy (letrozole/Femara®, anastrozole/Arimidex®, or fulvestrant/Faslodex®), by mouth or injection, daily or monthly, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">If you are premenopausal, you will also be given a therapy to stop your ovaries from producing estrogen</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Xentuzumab is an investigational targeted therapy that blocks insulin-like growth factor (IGF).</li> <li class="seamTextUnorderedListItem">Studies suggest it may improve how cancer cells respond to chemotherapy.</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer.</li> <li class="seamTextUnorderedListItem">The anti-estrogen drug you are given will be letrozole (Femara®), anastrozole (Arimidex®) or fulvestrant (Faslodex®).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03099174' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/xentuzumab' target='_blank'>NCI Drug Dictionary: Xentuzumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verzenio.com' target='_blank'>Eli Lilly and Company Drug Information Page: Verzenio® (Abemaciclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/view/xentuzumab-combination-shows-promise-in-advanced-breast-cancer' target='_blank'>Cure Today: Xentuzumab Combination Shows Promise in Advanced Breast Cancer</a> </li></ul>
See more
48

NEAREST SITE: 339 miles
UCLA
Santa Monica, CA

VISITS: 1 visit every 3 weeks

PHASE: I

NCT ID: NCT04064359

OBT076 in Advanced HER2 Negative Breast Cancer That Tests Positive for CD205

A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors and CD205+ HER2-negative Metastatic Breast Cancer Scientific Title

Purpose
To study the safety, best dose, and side effects (good and bad) of the investigational targeted therapy OBT076.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer whose tumor tests positive for the CD205 protein and who have no standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OBT076, by IV, every 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">OBT076 is a type of therapy called an antibody-drug conjugate (ADC). These therapies combine an antibody that can find the cancer cells with a drug that can kill them. </li> <li class="seamTextUnorderedListItem">The antibody in OBT076 targets the CD205 protein and delivers a drug to make the immune system see cancer cells.</li> <li class="seamTextUnorderedListItem">Targets or mutations: CD205</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04064359' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Antibody-drug_conjugate' target='_blank'>Wikipedia: Antibody-drug Conjugates</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/ChemotherapyandTargetedTherapy.html' target='_blank'>Susan G. Komen: Emerging Areas</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate' target='_blank'>NCI Dictionary of Cancer Terms: Antibody-drug Conjugate</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.aacr.org/from-the-journals-editors-picks-for-september/' target='_blank'>AACR Blog: Editors’ Picks for September</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.menarini.com/Home/Innovation-Research/MEN1309' target='_blank'>Drug Company Information Page: MEN1309 (OBT076)</a> </li></ul>
See more
49

NEAREST SITE: 339 miles
UCLA Hematology/Oncology Parkside
Santa Monica, CA

VISITS: 1 visit every 2 weeks, ongoing

PHASE: II

NCT ID: NCT04224272

Targeted Therapy ZW25, Palbociclib, & Fulvestrant for People with Advanced HER2+, HR+ Breast Cancer

Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant Scientific Title

Purpose
To assess the safety and effects (good and bad) of the experimental HER2-targeted therapy ZW25 when it is given with palbociclib (Ibrance®) and fulvestrant (Faslodex®).
Who is this for?
People who have advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+), hormone positive (ER+ and/or PR+) breast cancer; have previously been treated with trastuzumab (Herceptin®), pertuzumab (Perjeta®), or Trastuzumab emtansine/T-DM1 (Kadcyla®); and not have been treated with a CDK4/6 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZW25, by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily,</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, twice a month for the first month, then once a month, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZW25 is a new type of HER2-targeted therapy. </li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a type of targeted therapy called a CDK4/6 inhibitor. </li> <li class="seamTextUnorderedListItem">It is approved for use along with a hormone therapy to treat metastatic hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer.</li> <li class="seamTextUnorderedListItem">Faslodex is a hormone therapy approved to treat postmenopausal people with advanced breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04224272' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-her2-bi-specific-monoclonal-antibody-zw25' target='_blank'>NCI Drug Dictionary: ZW25</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ascopost.com/News/59508' target='_blank'>ASCO: Investigational Anti-HER2 Therapy in HER2-Expressing Solid Tumors</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/herceptin' target='_blank'>Breastcancer.org: Targeted Therapies</a> </li><li class='seamTextUnorderedListItem'><a href='https://dailynews.ascopubs.org/do/10.1200/ADN.19.190160/full/' target='_blank'>ASCO: The Role of CDK4 Inhibitors in Triple-Positive Breast Cancers</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-fulvestrant-breast-cancer' target='_blank'>NCI Cancer Currents Blog: FDA Expands Approval of Fulvestrant for Advanced Breast Cancer</a> </li></ul>
See more
50

NEAREST SITE: 339 miles
University of California Los Angeles (UCLA)
Santa Monica, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: I

NCT ID: NCT03330561

PRS-343 in HER2-Positive Advanced Breast Cancer

A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors Scientific Title

Purpose
To test the safety and effects (good and bad) of PRS-343, an experimental cancer drug.
Who is this for?
People with HER2-positive locally advanced (stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRS-343 by IV, every 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRS-343 is a new type of cancer treatment. </li> <li class="seamTextUnorderedListItem">The drug is a HER2-targeted therapy that also stimulates the immune system. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of solid tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03330561' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
51

NEAREST SITE: 339 miles
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology
Los Angeles, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT04503265

Dual PARP and Microtubule Polymerization Inhibitor AMXI-5001 for Advanced Breast Cancer.

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies Scientific Title

Purpose
To study the best dose, safety, and anti-cancer activity of AMXI-5001--an experimental PARP inhibitor.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMXI-5001, by mouth, twice daily (4 days on, 3 days off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AMX-5001 is an experimental PARP inhibitor.</li> <li class="seamTextUnorderedListItem">PARP inhibitors block poly (ADP-ribose) polymerase, an enzyme that helps cancer cells grow by repairing their DNA. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04503265' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://atlasmedx.com/product-pipeline/' target='_blank'>AtlasMedx Drug Information Page: AMXI-5001</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor' target='_blank'>NCI Drug Dictionary: PARP Inhibitor</a> </li></ul>
See more
52

NEAREST SITE: 339 miles
Angeles Clinic and Research Institute, The
Santa Monica, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04042480

SGN-CD228A For Advanced HER2 Negative Breast Cancer

A Phase 1 Study of SGN-CD228A in Select Advanced Solid Tumors Scientific Title

Purpose
To study the safety and effects (good and bad) of an antibody-drug conjugate called SGN-CD228A.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative breast cancer who have already been treated with a taxane. If your tumor is ER+, you must already have been treated with a CDK4/6 inhibitor and an anti-estrogen therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SGN-CD228A, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">An antibody-drug conjugate (ADC) is a type of cancer therapy that combines an antibody that targets cancer cells with a drug that can kill cancer cells. </li> <li class="seamTextUnorderedListItem">SGN-CD228A targets CD228, a protein found on several types of cancer cells. </li> <li class="seamTextUnorderedListItem">This study also is enrolling patients with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04042480' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.marketwatch.com/press-release/seattle-genetics-highlights-antibody-drug-conjugate-innovation-and-immuno-oncology-program-at-the-american-association-for-cancer-research-aacr-annual-meeting-2019-03-27' target='_blank'>Press Release: SGN-CD228A</a> </li></ul>
See more
53

NEAREST SITE: 341 miles
Cedars-Sinai Medical Center
Los Angeles, CA

VISITS: Please contact research site

PHASE: I

NCT ID: NCT03775525

GZ17-6.02 for Metastatic Breast Cancer (GEN602)

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Given Orally on a Daily x 28 Day Schedule in Patients With Advanced Solid Tumors or Lymphoma Scientific Title

Purpose
To study the safety and effects (good and bad) of a new type of cancer drug called GZ17-6.02.
Who is this for?
People with metastatic (stage IV) breast cancer who have no other available standard treatment options.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GZ17-6.02, by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Researchers have found that GZ17-6.02 blocks the super-enhancers that send signals for cells to grow. </li> <li class="seamTextUnorderedListItem">This study is also enrolling women with advanced endometrial cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03775525' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mct.aacrjournals.org/content/17/1_Supplement/LB-A26' target='_blank'>AACR Abstract: GZ17-6.02</a> </li></ul>
See more
54

NEAREST SITE: 341 miles
Cedars-Sinai Medical Center
Los Angeles, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: II

NCT ID: NCT03025035

Keytruda for Advanced BRCA+ Breast Cancer

Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Advanced BRCA-mutated Breast Cancers Scientific Title

Purpose
To look at the safety and effects (good and bad) of using the immunotherapy drug pembrolizumab (Keytruda®) to treat advanced or metastatic breast cancer in patients with a BRCA mutation.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer and have been tested and told that you have an inherited BRCA (BRCA1 or BRCA2) mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The immunotherapy is pembrolizumab (Keytruda®), </li> <li class="seamTextUnorderedListItem">Keytruda is approved to treat certain types of cancers, including breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03025035' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet' target='_blank'>NCI: BRCA1 and BRCA2</a> </li></ul>
See more
55

NEAREST SITE: 341 miles
Cedars-Sinai Medical Center
Los Angeles, CA

VISITS: 1 visit a week, then every 2 weeks, then every 3 weeks, ongoing

PHASE: II

NCT ID: NCT04383210

HER3 Inhibitor Seribantumab for People with Advanced Breast Cancer that is NRG1 Gene Fusion Positive

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors Scientific Title

Purpose
To study the anti-cancer activity, safety, and side effects of the experimental targeted therapy seribantumab.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer whose tumor tests positive for an NRG1 gene fusion and who have already received at least one therapy for advanced or metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Seribantumab, by IV, every week, then every 2 weeks, then every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Seribantumab is an experimental monoclonal antibody that binds to and blocks the HER3 protein. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: NRG1 gene fusion</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04383210' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/seribantumab' target='_blank'>NCI Drug Dictionary: Seribantumab</a> </li></ul>
See more
56

NEAREST SITE: 341 miles
Cedars-Sinai Medical Center - West Hollywood /ID# 204267
West Hollywood, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03595059

ABBV-155 for Advanced Breast (and Other) Cancers

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors Scientific Title

Purpose
To evaluate the safety of a new cancer drug ABBV-155 and to determine the best dose of the drug to use, and look at the effects (good and bad) of the best dose.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ABBV-155, by IV</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The experimental drug is called ABBV-155. It is only available in clinical trials. </li> <li class="seamTextUnorderedListItem">ABBV-155 will be given with paclitaxel (Taxol®) a drug approved to treat breast cancer. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03595059' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
57

NEAREST SITE: 341 miles
Cedars-Sinai Medical Center
Los Angeles, CA

VISITS: 3 visits every month, ongoing

PHASE: I

NCT ID: NCT03129139

Minnelide™ Capsules and Chemotherapy for Metastatic Breast Cancer

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of using Minnelide™ along with the chemotherapy drug protein-bound paclitaxel (Abraxane®).
Who is this for?
People with metastatic (stage IV) breast cancer and have no standard cancer treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Minnelide™, by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Abraxane® (protein-bound paclitaxel), by IV, once a week (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Minnelide™ is an experimental heat shock protein (HSP) inhibitor. </li> <li class="seamTextUnorderedListItem">Abraxane is used to treat metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03129139' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/protein-bound-paclitaxel' target='_blank'>NCI Dictionary of Cancer Terms: Protein-bound Paclitaxel</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/triptolide-analogue' target='_blank'>NCI Drug Dictionary: Triptolide Analogue (Minnelide™)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515388/' target='_blank'>Journal Article: Minnelide™ for Pancreatic and Liver Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.abraxane.com/mbc/' target='_blank'>Drug Company Information Page: Abraxane</a> </li></ul>
See more
58

NEAREST SITE: 341 miles
Cedar-Sinai
Beverly Hills, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: II

NCT ID: NCT03530696

T-DM1 and Palbociclib for Advanced HER2 Positive Breast Cancer

A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer Scientific Title

Purpose
To compare the side effects and effectiveness of the combination of T-DM1 (Kadcyla®) and palbociclib (Ibrance®) to T-DM1 (Kadcyla®) alone.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2-positive breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily, 2 weeks on, 1 week off </li> <li class="seamTextUnorderedListItem">T-DM1 (Kadcyla®), by IV, once every 3 weeks </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">T-DM1 (Kadcyla®), by IV, every 3 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Kadcyla® is a HER2-targeted therapy that combines the chemotherapy drug DM1 with the HER2 targeted therapy trastuzumab (Herceptin). </li> <li class="seamTextUnorderedListItem">It is approved for patients with previously treated HER2-positive metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">Ibrance® is a CDK4/6 inhibitor approved to treat metastatic breast cancer when given along with hormone therapy--either letrozole (Femara®) or fulvestrant (Faslodex®).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03530696' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cslide.ctimeetingtech.com/library/esmo/browse/search/258K#2F3503b' target='_blank'>ESMO: Palbociclib in combination with TDM1 for metastatic HER2+ breast cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/BreastCancer/RecommendedTreatmentsforMetastaticBreastCancer.html' target='_blank'>Susan G. Komen: Trastuzumab emtansine (T-DM1, Kadcyla)</a> </li></ul>
See more
59

NEAREST SITE: 341 miles
Cedars-Sinai Medical Center
Los Angeles, CA

VISITS: Coincides with type of therapy

PHASE: NA

NCT ID: NCT03098576

Molecular Tumor Profiling to Select Targeted Therapies for People With Advanced Breast Cancer

A Basket Study: Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute Scientific Title

Purpose
To study the effects (good and bad) of choosing a targeted therapy for treatment based on the results of molecular profiling of your tumor.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer. You must also have had at least one treatment your tumor did not respond to or progressed on.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups based on the results of your molecular profiling: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Matched targeted drug treatment</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive a drug that is targeted to a specific genetic abnormality (mutation) if one is found in your tumor</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of Care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">You will receive the standard of care therapy if no genetic abnormality (mutation) is found in your tumor</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular profiling is a process that identifies mutations and biomarkers in your tumor's DNA that have FDA-approved matched therapies or are eligible for clinical trials.</li> <li class="seamTextUnorderedListItem">In this study, a sample of your tumor will be analyzed (called molecular profiling) at Cedars-Sinai Medical Center in California.</li> <li class="seamTextUnorderedListItem">Targets or mutations: varies based on your test results</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03098576' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ww5.komen.org/KomenPerspectives/Tumor-profiling-–-personalizing-treatment-for-breast-cancer.html' target='_blank'>Susan G. Komen: Tumor Profiling--Personalized Treatment For Breast Cancer</a> </li></ul>
See more
60

NEAREST SITE: 342 miles
California Research Institute
Los Angeles, CA

VISITS: Weekly visits for 4 months

PHASE: I

NCT ID: NCT02626507

Gedatolisib, Ibrance and Faslodex Before Surgery in Women With ER+ HER2- Breast Cancer

Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer Scientific Title

Purpose
To test the safety and effects (good and bad) and best dose of the targeted therapy gedatolisib when used along with fulvestrant (Faslodex®) and palbociclib (Ibrance®).
Who is this for?
Women with ER-positive HER2-negative stage I, II, III or IV (metastatic) breast cancer who has not yet had any breast cancer treatments and is scheduled to have a lumpectomy or a mastectomy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following treatment before surgery: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gedatolisib, by IV, once a week for 4 months</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, twice a month in the first month, then monthly for the remaining 3 months</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily for 3 weeks each month</li> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by mouth, once a month, if needed</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The purpose of this study is to test the safety and effects (good or bad) and best dose of the targeted therapy gedatolisib when used along with fulvestrant (Faslodex®) and palbociclib (Ibrance®). </li> <li class="seamTextUnorderedListItem">The combination is given before surgery. This is called neoadjuvant treatment. </li> <li class="seamTextUnorderedListItem">Giving therapy before surgery allows researchers to study the effect the therapy has on the breast tumor. </li> <li class="seamTextUnorderedListItem">Gedatolisib kills cancer cells by blocking the PI3K/mTOR pathway. </li> <li class="seamTextUnorderedListItem">Faslodex® is a hormone therapy approved to treat advanced breast cancer in postmenopausal women. </li> <li class="seamTextUnorderedListItem">Ibrance® is a type of targeted therapy called a CDK 4/6 inhibitor. It is approved to treat metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">If you are premenopausal, you will also be given the drug goserelin (Zoladex®), which will put you in temporary menopause.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02626507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancer-news.com/2017/11/15/advanced-breast-cancer-therapy-combo-faslodex-fulvestrant-ibrance-palbociclib-approved-eu/' target='_blank'>Breast Cancer News: European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib' target='_blank'>NCI Drug dictionary: Palbociclib (Ibrance®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/fulvestrant' target='_blank'>NCI Drug dictionary: Fulvestrant (Faslodex®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/drugs/goserelinacetate' target='_blank'>NCI Drug dictionary: Goserelin (Zoladex®)</a> </li></ul>
See more
61

NEAREST SITE: 346 miles
Los Angeles Hematology Oncology Medical
Los Angeles, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: II

NCT ID: NCT04596150

CX-2009 Alone or with the Experimental PD-L1 Inhibitor CX-072 for Advanced HER2 Negative Breast Cancer

A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination With CX-072 in Advanced Triple-Negative Breast Cancer Scientific Title

Purpose
To study the safety and anti-cancer activity of giving CX-2009 alone and in combination with CX-072.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer or triple negative (ER-, PR-, HER2-) breast cancer that tests positive for high CD166 expression or is PD-L1 positive.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups and receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Hormone positive, HER2 negative</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009, by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Triple negative, CD166 expression</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009, by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Triple negative, PD-L1 positive</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009, by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">CX-072, by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CX-2009 is an experimental therapy that targets the protein CD166 on cancer cells to deliver the anti-cancer drug DM4.</li> <li class="seamTextUnorderedListItem">CX-072 is a type of an experimental immunotherapy called a PD-L1 inhibitor. </li> <li class="seamTextUnorderedListItem">Targets or mutations: CD166, PD-L1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04596150' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cytomx.com/pipeline/' target='_blank'>CytomX Therapeutics Drug Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.526' target='_blank'>Journal Abstract: CX-2009, a CD166-Directed Probody Drug Conjugate</a> </li><li class='seamTextUnorderedListItem'><a href='https://immuno-oncologynews.com/cx-072/' target='_blank'>Immunotherapy-Oncology News: CX-072</a> </li></ul>
See more
62

NEAREST SITE: 348 miles
University of Southern California
Los Angeles, CA

VISITS: 3 visits a month, ongoing

PHASE: II

NCT ID: NCT04225117

Targeted Therapy Enfortumab Vedotin in Advanced, HER2 Negative Breast Cancer

An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Scientific Title

Purpose
To study the antitumor activity and effects (good and bad) of the experimental targeted therapy enfortumab vedotin (AGS-22CE).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV), HER2 negative (HER2-) breast cancer who have received chemotherapy for advanced or metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enfortumab vedotin (ASG-22CE), by IV, weekly (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Enfortumab vedotin (ASG-22CE) is an antibody-drug conjugate. It combines an antibody that targets a specific protein on cancer cells (Nectin-4) with a chemotherapy drug that can kill them.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04225117' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-nectin-4-antibody-drug-conjugate-asg-22ce' target='_blank'>NCI Drug Dictionary: Enfortumab Vedotin</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/targeted-cancer-drugs/types/monoclonal-antibodies' target='_blank'>Cancer Research UK: Monoclonal Antibodies</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.seagen.com/science/pipeline/enfortumab-vedotin' target='_blank'>Seagen Drug Information Page: Enfortumab Vedotin</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.frontiersin.org/articles/10.3389/fmed.2019.00200/full' target='_blank'>Journal Article: Nectin-4 Expression Is an Independent Prognostic Biomarker and Associated With Better Survival in Triple-Negative Breast Cancer</a> </li></ul>
See more
63

NEAREST SITE: 348 miles
USC Norris Comprehensive Cancer Center
Los Angeles, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04526106

Targeted Therapy RLY-4008 for Advanced Breast Cancer with a FGFR2 Mutation, Fusion, or Amplification

A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors Scientific Title

Purpose
To study the best dose, safety, side effects, and ant-cancer activity of the experimental targeted therapy RLY-4008.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that tests positive for a FGFR2 mutation, fusion, or amplification.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RLY-4008, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">RLY-4008 is an experimental FGFR2 inhibitor. Researchers think inhibiting (blocking) the FGFR pathway may stop or slow the growth of certain tumors.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: FGFR2</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04526106' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://relaytx.com/pipeline/' target='_blank'>Relay Therapeutics Drug Information Page: RLY-4008</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071019/' target='_blank'>Journal Article: Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer</a> </li></ul>
See more
64

NEAREST SITE: 348 miles
USC/Norris Cancer Center
Los Angeles, CA

VISITS: Visits weekly, ongoing

PHASE: I

NCT ID: NCT02892123

A HER2-Targeted Drug for Advanced HER2-Positive Breast Cancer

Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers Scientific Title

Purpose
To investigate whether a new type of HER2-targeted drug is safe and effective. It will also determine the most effective dose of the drug that can be used safely.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive breast cancer. You must have already received at least one treatment for your cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZW25, by IV, weekly, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The drug being studied is called ZW25. </li> <li class="seamTextUnorderedListItem">This study is also open to patients with other types of HER2-positive cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02892123' target='_blank'>ClinicalTrials.gov</a> </li></ul>
See more
65

NEAREST SITE: 348 miles
Research Site
Los Angeles, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT02264678

Ceralasertib Alone or With Chemotherapy or With Olaparib in Advanced Breast Cancer

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies. Scientific Title

Purpose
To study the safety, effects, and best dose of Ceralasertib when it is used alone or with the chemotherapy drug carboplatin or the PARP inhibitor olaparib (Lynparza®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Open to all MBC patients</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib, by mouth </li> <li class="seamTextUnorderedListItem">Carboplatin (Paraplatin®), by IV, every 3 weeks for up to 4.5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Open to all MBC patients </i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3: Open to Triple Negative Breast Cancer MBC patients with or without a BRCA mutation</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib, by mouth</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">3 biopsies</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ceralasertib is a new type of targeted therapy called an ATR inhibitor. </li> <li class="seamTextUnorderedListItem">It disrupts a cancer cell's ability to repair its own DNA, which can cause the cancer cells to die. </li> <li class="seamTextUnorderedListItem">Carboplatin is a chemotherapy drug used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">Lynparza is a PARP inhibitor approved to treat BRCA 1 or BRCA 2 positive metastatic breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02264678' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-azd6738' target='_blank'>NCI Drug Dictionary: Ceralasertib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/olaparib' target='_blank'>NCI Drug Dictionary: Olaparib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/publications/oncology-live/2018/vol-19-no-24/targeting-cancers-achilles-heel-dna-damage-response-networks-beyond-parp' target='_blank'>OncLive: DNA Damage Response Networks Beyond PARP</a> </li></ul>
See more
66

NEAREST SITE: 348 miles
USC Norris
Los Angeles, CA

VISITS: 1 visit per month, for 5 months

PHASE: I-II

NCT ID: NCT03058289

INT230-6 Injections & Immunotherapy in Advanced Breast Cancer

A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers Scientific Title

Purpose
To study the effects (good and bad) of giving INT230-6 alone and with an anti-PD-1 immunotherapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer. You must have no standard of care treatments available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">INT230-6, by injection, into your tumor, monthly, for 5 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">If you are in the combination treatment cohort, you will also receive an anti-PD1 drug (schedule determined by the physician)</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">INT230-6 is a combination chemotherapy treatment that is injected directly into the tumor. </li> <li class="seamTextUnorderedListItem">INT230-6 contains the chemotherapy drugs cisplatin (Platinol®) and vinblastine (Velban®) along with a substance that makes them more effective.</li> <li class="seamTextUnorderedListItem">This study is also recruiting patients with other types of advanced cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03058289' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://intensitytherapeutics.com/products/lead-product-int230-6/' target='_blank'>Drug Company Information Page: INT230-6</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/what' target='_blank'>Breastcancer.org: Immunotherapy</a> </li></ul>
See more
67

NEAREST SITE: 348 miles
USC Norris Comprehensive Cancer Center and HOAG
Los Angeles, CA

VISITS: Every 3 weeks, ongoing

PHASE: I

NCT ID: NCT04250597

Targeted Therapy GNX102 in Advanced Breast Cancer

A Phase I Study of GNX102 in Patients With Advanced Solid Tumors Scientific Title

Purpose
To study the safety and anti-cancer activity of the experimental targeted therapy GNX102.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GNX102, by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GNX102 is an experimental targeted therapy. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04250597' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.glyconex.com.tw/index.php/en-us/product-pipeline-us' target='_blank'>Glyconex Drug Information Page: GNX102</a> </li></ul>
See more
68

NEAREST SITE: 353 miles
Research Site
Duarte, CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT04494425

Trastuzumab Deruxtecan or Chemotherapy for Metastatic HR+, HER2-Low Breast Cancer

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Scientific Title

Purpose
To compare the anti-cancer activity, safety, and side effects of giving trastuzumab deruxtecan (Enhertu®) to giving chemotherapy.
Who is this for?
People with metastatic (stage IV) hormone-positive (ER+ and/or PR+), HER2-Low breast cancer who have already received at least one anti-hormone therapy for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab deruxtecan (Enhertu®), by IV, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Your doctor's choice of chemotherapy: capecitabine (Xeloda®), paclitaxel (Taxol®), or nab-paclitaxel (Abraxane®) ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab Deruxtican (Enhertu®) is an antibody-drug conjugate (ADC). It targets HER2 to deliver a chemotherapy drug directly to the cancer cells. It is approved to treat people with metastatic HER2+ breast cancer who have already received two anti-HER2 therapies. Its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">The chemotherapies capecitabine (Xeloda®), paclitaxel (Taxol®), and nab-paclitaxel (Abraxane®) are all commonly used to treat metastatic breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04494425' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/her2-low-expressing-a-new-subcategory-of-her2-negative-breast-cancer/' target='_blank'>Metastatic Trial Talk: HER2-Low Expressing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.enhertu.com/en/gastric/?utm_source=google&utm_medium=cpc&utm_campaign=branded+general_2020&utm_content=branded+general_exact&utm_term=trastuzumab+deruxtecan&gclid=cj0kcqias5ecbhcbarisaehk4r7igokn76-yzybu0ziqrknxg5sw-w0t3uyeq-25nhutdetkzoiiwuua' target='_blank'>Daiichi Sankyo Company Drug Information Page: Enhertu® (Fam-Trastuzumab Deruxtican-nxki)</a> </li></ul>
See more
69

NEAREST SITE: 353 miles
Site 5
Los Angeles, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03560531

Targeted Therapy ZN-c5 For Advanced Breast Cancer

A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Previously Treated Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer Scientific Title

Purpose
To look at the safety, best dose and effects (good and bad) of ZN-c5 when it is used alone or in combination with palbociclib (Ibrance®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have already been treated with a hormone therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c5, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c5, by mouth</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c5 is an investigational anti-cancer drug. </li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a targeted drug used to treat metastatic breast cancer in combination with a hormone therapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03560531' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/ibrance' target='_blank'>Breastcancer.org: Ibrance</a> </li></ul>
See more
70

NEAREST SITE: 353 miles
City of Hope National Medical Center
Duarte, CA

VISITS: May require hospital stay

PHASE: I

NCT ID: NCT04650451

Experimental CAR T-Cell Immunotherapy BPX-603 for Advanced HER2 Positive Breast Cancer

A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors Scientific Title

Purpose
To study the safety, best dose and effects (good and bad) of an experimental CAR T-cell immunotherapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have no standard of care treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BPX-603 (CAR T-cell immunotherapy), by IV, one time</li> <li class="seamTextUnorderedListItem">Rimiducid, by IV, weekly</li> <li class="seamTextUnorderedListItem">You may also receive, temsirolimus, by IV, one time</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BPX-603 is the experimental CAR T-cell immunotherapy used in this trial.</li> <li class="seamTextUnorderedListItem">CAR T-cell therapy is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so that they can attack a specific protein.</li> <li class="seamTextUnorderedListItem">The CAR T-cells are then infused back into you while you are hospitalized.</li> <li class="seamTextUnorderedListItem">The CAR T-cell therapy being used in this study trains the immune system to attack HER2+ cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of HER2 positive cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04650451' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html' target='_blank'>American Cancer Society: CAR T-cell Therapy and Its Side Effects</a> </li></ul>
See more
71

NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte, CA

VISITS: May require hospitalization

PHASE: I

NCT ID: NCT03696030

CAR T-Cell Immunotherapy in HER2+ Breast Cancer with Brain or Leptomeningeal Metastases

A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers Scientific Title

Purpose
To study the safety, best dose, and effects (good and bad) of a CAR T-cell immunotherapy that is delivered directly into the brain.
Who is this for?
People with metastatic (stage IV) HER2 positive (HER2+) breast cancer with brain or leptomeningeal metastases.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw to collect white blood cells to make your HER2 CAR T-cell therapy (leukapheresis)</li> <li class="seamTextUnorderedListItem">Surgery to place a device (similar to a chemotherapy port) under your scalp</li> <li class="seamTextUnorderedListItem">HER2 CAR T-cells, by injection, weekly, 3 times</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule. Hospital stay may be required.</i> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Follow up</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Every 2 months for 1 year, then every year for 15 years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads to the membranes surrounding the brain and/or the spinal cord (leptomeninges) or to the cerebrospinal fluid.</li> <li class="seamTextUnorderedListItem">CAR T-cell therapy is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so that they can attack a specific protein.</li> <li class="seamTextUnorderedListItem">The CAR T-cells are then infused back into you while you are hospitalized. </li> <li class="seamTextUnorderedListItem">The CAR T-cell therapy being used in this study trains the immune system to attack HER2+ cancer cells.</li> <li class="seamTextUnorderedListItem">You will have surgery to insert a device under your scalp so that the CAR T-cell therapy can be infused directly into your brain.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03696030' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cityofhope.org/physician-news/breast-cancer-car-t-cell-therapy' target='_blank'>City of Hope Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html' target='_blank'>American Cancer Society: CAR T-cell Therapy and Its Side Effects</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Leukapheresis' target='_blank'>Wikipedia: Leukapheresis</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Metastases</a> </li></ul>
See more
72

NEAREST SITE: 353 miles
City of Hope
Duarte, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04348916

ONCR-177 Alone or With Pembrolizumab in Advanced Breast Cancer

A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors Scientific Title

Purpose
To study the best dose and anti-cancer activity of giving the genetically modified virus ONCR-177 alone and in combination with the immunotherapy pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ONCR-177, by injection, directly into your tumor</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ONCR-177, by injection, directly into your tumor</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ONCR-177 is an Oncolytic Herpes Simplex Virus--this is a herpes virus that has been genetically modified to destroy cancer cells. Researchers believe it will also work as an immunotherapy.</li> <li class="seamTextUnorderedListItem">ONCR-177 is injected directly into the tumor. </li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. It gets the immune system to go after cancer cells.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is approved to treat only certain types of breast cancer and its use in this trial is considered experimental. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04348916' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://static1.squarespace.com/static/59df87cbd7bdceb69ad86d5a/t/5ca4c245e5e5f0302a360460/1554301532888/Design+of+ONCR-177+base+vector.pdf' target='_blank'>Drug Company Information Page: ONCR-177</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Oncolytic_herpes_virus' target='_blank'>Wikipedia: Oncolytic Herpes Virus</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Information Page: Keytruda® (Pembrolizumab)</a> </li></ul>
See more
73

NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04305834

Effects of Abemaciclib in People 70 or Older With Metastatic Hormone Positive Breast Cancer

A Phase IIA Trial Assessing the Tolerability of Abemaciclib Monotherapy in Patients Age 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer Scientific Title

Purpose
To study the side effects (good and bad) of abemaciclib (Verzenio®).
Who is this for?
People with metastatic (stage IV), hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are age 70 or older and have already received treatment for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04305834' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verzenio.com' target='_blank'>Drug Company Information Page: Verzenio® (Abemaciclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/verzenio' target='_blank'>Breastcancer.org: Abemaciclib (Verzenio®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcrf.org/blog/breast-cancer-elderly-how-bcrf-researchers-are-treating-growing-patient-population' target='_blank'>Breast Cancer Research Foundation: Breast Cancer in the Elderly</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249663/' target='_blank'>Journal Article: Use of Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors in Older Patients</a> </li></ul>
See more
74

NEAREST SITE: 356 miles
Investigational Site Number 8400032
Torrance, CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT04478266

An Experimental Anti-Estrogen Therapy and a CDK 4/6 Inhibitor for Advanced, ER+, HER2- Breast Cancer

A Randomized, Multicenter, Double-blind Phase 3 Study of SAR439859 Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease Scientific Title

Purpose
To compare the anti-cancer activity and safety of giving the experimental anti-estrogen therapy SAR439859 in combination with palbociclib (Ibrance®) to giving the standard anti-estrogen therapy letrozole (Femara®) in combination with palbociclib.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have not yet had treatment for advanced or metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental: SAR439859 and Palbociclib</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR439859, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by injection, monthly, ongoing (if you are a pre/perimenopausal woman or a man)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard Care: Letrozole and Palbociclib</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by injection, monthly, ongoing (if you are a pre/perimenopausal woman or a man)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR439859 is a type of experimental anti-estrogen therapy called a selective estrogen receptor degrader (SERD). </li> <li class="seamTextUnorderedListItem">Letrozole (Femara®) is a type of hormone therapy called an aromatase inhibitor. It is commonly used to treat hormone-sensitive breast cancer.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is a type of targeted therapy called a CDK4/6 inhibitor. It is approved for treating metastatic hormone positive, HER2 negative breast cancer.</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®) is commonly used in combination with either letrozole (Femara®) or fulvestrant (Faslodex®).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04478266' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/treatment-of-breast-cancer-by-stage/treatment-of-stage-iv-advanced-breast-cancer.html' target='_blank'>American Cancer Society: Treatment of Stage IV (Metastatic) Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/ibrance' target='_blank'>Breastcancer.org: Palbociclib (Ibrance®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.onclive.com/view/next-generation-endocrine-therapy-moves-forward-in-breast-cancer-trial' target='_blank'>OncLive: Next-Generation Endocrine Therapy Moves Forward in Breast Cancer Trial</a> </li></ul>
See more
75

NEAREST SITE: 363 miles
Pacific Shores Medical Group
Long Beach, CA

VISITS: 1 visit every 3 weeks, ongoing

PHASE: II

NCT ID: NCT04579380

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations Scientific Title

Purpose
To study the anti-cancer activity and side effects of giving the anti-HER2 targeted therapies tucatinib (Tukysa®) and trastuzumab (Herceptin®) for HER2 negative breast cancer.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV), HER2 negative (HER2-) breast cancer whose disease progressed after receiving therapy for advanced disease. Your tumor must also test positive for a HER2/ERBB mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®), by mouth, twice daily, ongoing</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, once a month, ongoing (only if your disease is hormone positive)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tucatinib (Tukysa®) is an anti-HER2-targeted therapy approved for use in HER2 positive breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is an anti-HER2 targeted therapy routinely used for HER2 positive breast cancer, but its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: HER2/ERBB</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04579380' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.tukysa.com/?&utm_source=GOOGLE&utm_medium=cpc&utm_campaign=GS_Brand_Fullsite_Alone_PI&utm_content=General_EX&utm_term=tucatinib&gclsrc=ds&gclid=CjwKCAiA9bmABhBbEiwASb35V8_ibwE-Ey-u91KsJCshbmkozNCJ60FlvCmi5bs3npzhPRr6KigNdBoC4VgQAvD_BwE&gclsrc=' target='_blank'>Seagen Drug Information Page: Tukysa® (Tucatinib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Trastuzumab' target='_blank'>Wikipedia: Trastuzumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer' target='_blank'>FDA: FDA Approves Tucatinib for Patients with HER2-Positive Metastatic Breast Cancer</a> </li></ul>
See more
76

NEAREST SITE: 363 miles
Pacific Shores Medical Group
Long Beach, CA

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04172597

Poziotinib for Metastatic Breast Cancer with EGFR or HER2 Gene Mutations

A Phase 2 Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Scientific Title

Purpose
To study the safety, effects (good and bad), and anti-tumor activity of the experimental targeted therapy poziotinib hydrochloride (HM781-36B).
Who is this for?
People with metastatic (stage IV) breast cancer who have no standard treatment options available. Your tumor must test positive for certain EGFR or HER2 (ERBB2) gene mutations. (See below for complete list of targets or mutations.)    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A biopsy so that your tumor can be tested for certain genetic mutations</li> <li class="seamTextUnorderedListItem">Poziotinib hydrochloride (HM781-36B), by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Poziotinib hydrochloride (HM781-36B) is designed to target tumors with certain HER and EGFR related mutations. </li> <li class="seamTextUnorderedListItem">Targets or mutations: HER2 (ERBB2), EGFR, Furin-Like/Extracellular, S310F/Y Transmembrane, I655V, V659E, R678Q, V697L, Exon 20 insertion, T733I, L755X, I767M, D769H/N/Y, V773M, V777L/M, L786V, V842I, T862I, L869R EGFRvIII, R108K, R222C, A289T, P596L, G598V, E709K, G719X, V742I, E746 A750del, S768I, V769M, V774M, R831C, R831H, L858R, L861Q, A864V</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04172597' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.nationalbreastcancer.org/breast-cancer-targeted-therapy' target='_blank'>National Breast Cancer Foundation: Targeted Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/poziotinib' target='_blank'>NCI Drug Dictionary: Poziotinib Hydrochloride (HM781-36B)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.html' target='_blank'>American Cancer Society: Targeted Therapy for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/23422737' target='_blank'>Journal Abstract: Antitumor activity of HM781-36B, a Pan-HER Tyrosine Kinase Inhibitor, in HER2-amplified Breast Cancer Cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/30094493' target='_blank'>Journal Abstract: Activating Human Epidermal Growth Factor Receptor 2 (HER2) Gene Mutation in Bone Metastases From Breast Cancer.</a> </li></ul>
See more
77

NEAREST SITE: 363 miles
Pacific Shores Medical Group
Long Beach, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT04209465

BDTX-189 in Metastatic Breast Cancer That Tests Positive for or Expresses Certain Markers

MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies Scientific Title

Purpose
To study the safety, effects (good and bad), best dose, and anti-cancer activity of the experimental targeted therapy BDTX-189.
Who is this for?
People with metastatic (stage IV) breast cancer whose tumor tests positive or expresses one of several markers. (See below for a list of markers.)    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BDTX-189, by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BDTX-189 targets certain mutations in the ErbB (HER) group of receptor tyrosine kinases. </li> <li class="seamTextUnorderedListItem">People with other types of metastatic breast cancer are also being enrolled in this study.</li> <li class="seamTextUnorderedListItem">Targets or mutations: HER1 (ERBB1), allosteric HER2 (ERBB2), HER3 (ERBB3), EGFR, HER2 exon 20 insertion, HER2 positive, EGFR exon 19 deletion, or L858R</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04209465' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/' target='_blank'>Drug Company Information Page: BDTX-189</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies' target='_blank'>Breastcancer.org: Targeted Therapies</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/25435079' target='_blank'>Article Abstract: Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer.</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.frontiersin.org/articles/10.3389/fonc.2013.00086/full' target='_blank'>Journal Article: Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment</a> </li></ul>
See more
78

NEAREST SITE: 374 miles
Univ of California Irvine College of Medicine
Orange, CA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04188548

LY3484356 Alone or With Abemaciclib in Advanced ER+, HER2- Breast Cancer

A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Abemaciclib to Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer Scientific Title

Purpose
To study the safety and effects (good and bad) of LY3484356 when it is given alone or with abemaciclib (Verzenio®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that has been treated with at least one standard of care therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3484356, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3484356, by mouth</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsies (tissue samples)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3484356 is an experimental drug. </li> <li class="seamTextUnorderedListItem">Verzenio® is a type of targeted therapy called a CDK 4/6 inhibitor. It is approved to treat metastatic ER positive and/or PR positive, HER2- breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04188548' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lillytrialguide.com/en-US/studies/breast-cancer/jzla' target='_blank'>Eli Lilly & Company Study Information</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.verzenio.com/?utm_source=google&utm_medium=ppc&campaign=6456675261&adgroup=82640243172&ad=378689406880&utm_keyword=kwd-389189556877&gclid=CjwKCAiA1L_xBRA2EiwAgcLKA1TCNjqFBHZ6GUcDnbYuJPCiPuF9GkpS2yp7gF3j1LJCZnLEMhSm_RoCO0QQAvD_BwE' target='_blank'>Eli Lilly & Company Drug Information Page: Verzenio® (Abemaciclib)</a> </li></ul>
See more
79

NEAREST SITE: 421 miles
Comprehensive Cancer Centers of Nevada
Las Vegas, NV

VISITS: 2 visit every month, ongoing

PHASE: I

NCT ID: NCT03565445

ASP1948 Immunotherapy For Advanced Breast Cancer

A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With Nivolumab in Subjects With Advanced Solid Tumors Scientific Title

Purpose
To evaluate the safety and effects of using ASP1948 alone or with nivolumab (Opdivo®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that has not responded to other treatment options.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASP1948, by IV, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASP1948, by IV, every 2 weeks </li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 2 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASP1948 is an investigational immunotherapy that may stimulate an immune response against your cancer cells. </li> <li class="seamTextUnorderedListItem">Opdivo is a type of immunotherapy called a PD-1 (programmed cell death-1) inhibitor. By blocking this protein, immune cells are able to see and kill cancer cells. </li> <li class="seamTextUnorderedListItem">Opdivo is approved to treat certain types of advanced cancers. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This clinical trial is also enrolling patients with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03565445' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795699' target='_blank'>NCI Drug Dictionary: ASP1948</a> </li></ul>
See more
80

NEAREST SITE: 434 miles
California Cancer Associates for Research & Excellence, Inc.
San Marcos, CA

VISITS: Number of visits unavailable

PHASE: III

NCT ID: NCT04546009

GDC-9545 or Letrozole with Palbociclib for Advanced ER+, HER2- Breast Cancer

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Scientific Title

Purpose
To compare the safety and anti-cancer activity of giving palbociclib (Ibrance®) with the anti-estrogen therapy letrozole (Femara®) to giving palbociclib with the experimental anti-estrogen therapy GDC-9545.
Who is this for?
People with locally advanced (some stage III) or metastatic (stage IV), estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have not yet started treatment for advanced or metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups and receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-9545, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Letrozole (Femara®), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), a CDK 4/6 inhibitor, is commonly used in combination with either letrozole (Femara®) or fulvestrant (Faslodex®) for metastatic, hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer.</li> <li class="seamTextUnorderedListItem">GDC-9545 is an experimental anti-estrogen therapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04546009' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/hormonal-therapy-metastatic-breast-cancer' target='_blank'>ASCO Cancer.Net: Hormonal Therapy for Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/giredestrant' target='_blank'>NCI Drug Dictionary: GDC-9545</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/cdk46-inhibitors' target='_blank'>Breastcancer.org: CDK4/6 Inhibitors</a> </li></ul>
See more
81

NEAREST SITE: 441 miles
UCSD Moores Cancer Center
San Diego, CA

VISITS: Weekly visits for 3 weeks

PHASE: I

NCT ID: NCT03841110

FT500 Alone or With Immunotherapy for Advanced HER2-positive Breast Cancer

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1) Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of giving FT500 alone or with immunotherapy.
Who is this for?
People with HER2-positive advanced (some stage III) or metastatic (stage IV) breast cancer. Your cancer must have progressed after being treated with nivolumab (Opdivo®), pembrolizumab (Keytruda®) or atezolizumab (Tecentriq®).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT500, by IV, weekly, for 3 weeks</li> <li class="seamTextUnorderedListItem">Cyclophosphamide and Fludarabine</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT500, by IV, weekly for 3 weeks</li> <li class="seamTextUnorderedListItem">Combined with an Immune Checkpoint Inhibitor: Nivolumab (Opdivo®), Pembrolizumab (Keytruda®) or Atezolizumab (Tecentriq®) </li> <li class="seamTextUnorderedListItem">Cyclophosphamide and Fludarabine</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FT500 is a natural killer (NK) cell immunotherapy. </li> <li class="seamTextUnorderedListItem">NK cells are specialized immune cells that can fight cancer cells. </li> <li class="seamTextUnorderedListItem">Cyclophosphamide and fludarabine are chemotherapy drugs used to deplete lymph cells.</li> <li class="seamTextUnorderedListItem">Opdivo, Tecentriq and Keytruda are each a type of immunotherapy drug called a PD-1 (programmed cell death-1) inhibitor. They are approved to treat certain other types of cancers, but their use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03841110' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.ucsd.edu/news/releases/Pages/2019-04-01-UC-San-Diego-Health-Treats-Cancer-Patient-with-Stem-Cell-Derived-Natural-Killer-Cells.aspx' target='_blank'>UCSD Health: UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.the-scientist.com/news-opinion/clinical-trial-underway-for-a-natural-killer-cell-therapy-65845' target='_blank'>The Scientist: Clinical Trial Underway for a Natural Killer Cell Therapy</a> </li></ul>
See more
82

NEAREST SITE: 441 miles
University of California, San Diego
La Jolla, CA

VISITS: 1 visit a week, ongoing

PHASE: I

NCT ID: NCT02776917

A New Targeted Therapy and Paclitaxel for Advanced Breast Cancer

A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer Scientific Title

Purpose
To investigate the safety and effects (good and bad) of an experimental targeted therapy cirmtuzumab when it is given with the chemotherapy paclitaxel (Taxol®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cirmtuzumab, by IV, weekly (2 weeks on, 2 weeks off), over 6 months</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, ongoing</li> <li class="seamTextUnorderedListItem">Blood and tissue sample collection</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The experimental targeted therapy is cirmtuzumab. It targets ROR1, a protein found only on cancer cells.</li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®) is approved and commonly used for people with metastatic breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02776917' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://health.ucsd.edu/news/releases/Pages/2018-08-27-researchers-to-test-novel-drug-combination-against-toughest-breast-cancer.aspx' target='_blank'>UC San Diego Health: Researchers to Test Novel Drug Combination Against Toughest Breast Cancers</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancerres.aacrjournals.org/content/80/4_Supplement/P3-10-18' target='_blank'>ASCO Abstract: Cirmtuzumab and Paclitaxel for Locally Advanced, Unresectable and Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://oncternal.com/pipeline/cirmtuzumab' target='_blank'>Oncternal Therapeutics Drug Information Page: Cirmtuzumab</a> </li></ul>
See more
83

NEAREST SITE: 454 miles
Sharp Memorial Hospital
San Diego, CA

VISITS: At least 4 visits over 1 month

PHASE: I

NCT ID: NCT00986661

PV-10 Chemoablation for Breast Cancer That Has Spread to The Liver

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant Scientific Title

Purpose
To look at the safety and effects (good and bad) of a PV-10 injection into the liver.
Who is this for?
People with stage IV (metastatic) breast cancer that has spread to the liver.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PV-10, by injection</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Follow up</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Visits every 3 months for up to 8 years</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PV-10 targets and concentrates in tumor cells. </li> <li class="seamTextUnorderedListItem">When used along with radiation, it may make radiation more effective. </li> <li class="seamTextUnorderedListItem">It also may get the immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">This study will also include patients who have liver cancer or who have other types of cancers that have spread to the liver.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT00986661' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://provectusbio.com/pv-10-for-cancers-of-the-liver' target='_blank'>Drug company information page: PV-10 For Cancers of the Liver</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pv-10' target='_blank'>NCI Drug Dictionary: PV-10</a> </li></ul>
See more
84

NEAREST SITE: 456 miles
Scripps Health
San Diego, CA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03601897

Rebastinib and Paclitaxel in People with Metastatic Breast Cancer

An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of using the experimental drug rebastinib along with paclitaxel (Taxol®)
Who is this for?
People with metastatic breast cancer. You must have received prior treatment for metastatic breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rebastinib (DCC-2036), by mouth</li> <li class="seamTextUnorderedListItem">Paclitaxel, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Rebastinib is an investigational targeted therapy. </li> <li class="seamTextUnorderedListItem">Taxol is a chemotherapy drug used to treat breast cancer. </li> <li class="seamTextUnorderedListItem">This study is also enrolling women with ovarian cancer and endometrial cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03601897' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.deciphera.com/pipeline/rebastinib/' target='_blank'>Sponsor Site & Drug Company Information Page: Rebastinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/druglist/taxol' target='_blank'>Breastcancer.org: Taxol</a> </li><li class='seamTextUnorderedListItem'><a href='https://malebreastcancercoalition.org' target='_blank'>Male Breast Cancer Coalition</a> </li></ul>
See more
85

NEAREST SITE: 531 miles
Northwest Cancer Specialists - Portland (SW Barnes Rd)
Tigard, OR

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04576455

The Experimental Anti-Estrogen Therapy GDC-9545 for Advanced ER+, HER2- Breast Cancer

A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Scientific Title

Purpose
To compare the safety and anti-cancer activity of the experimental anti-estrogen therapy GDC-9545 to currently approved anti-hormone therapies.
Who is this for?
People with locally advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have already received one or two therapies for advanced or metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups and receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-9545, by mouth, daily ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Your doctor's choice of anti-hormone therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) or an aromatase inhibitor</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-9545 is an experimental anti-estrogen therapy.</li> <li class="seamTextUnorderedListItem">Anti-estrogen therapies currently approved to treat advanced breast cancer include fulvestrant (Faslodex®) and the aromatase inhibitors: anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04576455' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/giredestrant' target='_blank'>NCI Drug Dictionary: GDC-9545</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet' target='_blank'>NCI: Hormone Therapy for Breast Cancer</a> </li></ul>
See more
86

NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland, OR

VISITS: Number of visits varies based upon assigned treatment

PHASE: I

NCT ID: NCT03878524

Personalized Medicine For People With Metastatic Breast Cancer (SMMART)

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial Scientific Title

Purpose
To study the safety and effects (good and bad) of having your therapy selected by a group of doctors based on genomic testing of your tumor.
Who is this for?
People with metastatic (stage IV) breast cancer. Your tumor must test positive for or express one of several markers. (See below for a list of markers.)    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy</li> <li class="seamTextUnorderedListItem">Testing of your tumor sample to identify biomarkers</li> <li class="seamTextUnorderedListItem">A combination of two drugs selected from 35 possible drugs</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">This process may be repeated if your disease progresses</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A group of doctors will make a treatment decision for you by studying your tumor's genetic profile (this is called genomic testing).</li> <li class="seamTextUnorderedListItem">The group of doctors will choose 2 drugs out of 35 to give to you. </li> <li class="seamTextUnorderedListItem">The types of drugs available include: targeted therapies, immunotherapies, and chemotherapies. </li> <li class="seamTextUnorderedListItem">This type of study is called a basket trial. Basket studies enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ABL, BCL2, BRAF, CDK4, CDK6, COX-2, CSF-1R, CTLA-4, EGF, EGFR, FGFR, FLT3, HDAC, HER2 (ERBB2), JAK1/2, KIT, MEK, MET, mTOR, PARP, PD-1, PDGFR, PI3Kdelta, RAF, RET, VEGF, VEGF ligand, VEGFR</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03878524' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ohsu.edu/spatial-systems-biomedicine-center/serial-measurements-molecular-and-architectural-responses' target='_blank'>Oregon Health & Science University: SMMART program</a> </li><li class='seamTextUnorderedListItem'><a href='https://news.ohsu.edu/2018/11/16/making-cancer-clinical-trials-smmart' target='_blank'>Oregon Health & Science University NEWS: Making cancer clinical trials SMMART</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/diagnosis/genomic_assays' target='_blank'>Breastcancer.org: Tumor Genomic Assay Testing</a> </li></ul>
See more
87

NEAREST SITE: 535 miles
Providence Portland Medical Center; Providence Oncology and Hematology Clinic Westside
Portland, OR

VISITS: At least 1 visit every month, ongoing

PHASE: II-III

NCT ID: NCT04191499

Palbociclib, & Fulvestrant With or Without GDC-0077 in Advanced HR+, HER2- Breast Cancer with a PIK3CA Mutation

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer Scientific Title

Purpose
To compare the safety, effects (good and bad), and anti-cancer activity of using GDC-0077 with palbociclib (Ibrance®) and fulvestrant (Faslodex®) to using only Ibrance® and Faslodex®.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that the study investigator finds tests positive for a PIK3CA mutation. You must have received hormone therapy for early stage disease and have not already started treatment for metastatic breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-0077, by mouth, daily</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) by injection, once a month</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Placebo, by mouth, daily</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily (3 weeks on, 1 week off)</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) by injection, once a month</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GDC-0077 is an experimental targeted therapy that blocks the PI3K pathway.</li> <li class="seamTextUnorderedListItem">Ibrance® is a type of targeted therapy called a CDK4/6 inhibitor. It is used along with a hormone therapy to treat advanced HR positive, HER2 negative breast cancer. </li> <li class="seamTextUnorderedListItem">Faslodex is a hormone therapy used to treat advanced HR positive breast cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04191499' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-inhibitor-gdc-0077' target='_blank'>NCI Drug Dictionary: GDC-0077</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies' target='_blank'>Breastcancer.org: Targeted Therapies for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.curetoday.com/publications/cure/2019/breast-2019/a-brighter-outlook-for-metastatic-breast-cancer' target='_blank'>Cure Today: A Brighter Look for Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ibrance.com/about-ibrance?src_code=IBRW10028851#faq' target='_blank'>Pfizer Oncology: Ibrance® (Palbociclib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/fda-expands-use-of-faslodex-for-bc' target='_blank'>Breastcancer.org: FDA Expands Use of Faslodex for Breast Cancer</a> </li></ul>
See more
88

NEAREST SITE: 538 miles
Providence Oncology & Hematology Care Clinic - Eastside
Portland, OR

VISITS: 1 visit every 2 weeks

PHASE: II

NCT ID: NCT03650894

Nivolumab with Ipilimumab and Bicalutamide for Advanced HER2 Negative Breast Cancer

A Phase II Study of Nivolumab Combined With Bicalutamide and Ipilimumab in Metastatic HER2-negative Breast Cancer Scientific Title

Purpose
To test the safety and effects (good and bad) of using a combination of nivolumab (Opdivo®), ipilimumab (Yervoy®), and bicalutamide (Casodex®).
Who is this for?
Women with advanced (some stage III) or metastatic (stage IV) breast cancer HER2 negative breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 2 weeks</li> <li class="seamTextUnorderedListItem">Ipilimumab (Yervoy®), by IV, every 6 weeks</li> <li class="seamTextUnorderedListItem">Bicalutamide (Casodex®), by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Opdivo® is a type of immunotherapy that gets the immune system to go after cancer cells by blocking a protein called PD-1 (programmed cell death 1). </li> <li class="seamTextUnorderedListItem">Yervoy is an immunotherapy that works by blocking a protein called CTLA-4. </li> <li class="seamTextUnorderedListItem">Yervoy and Opdivo are approved to be used together to treat patients with melanoma and certain other cancers. Their use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Casodex is an anti-androgen drug used to treat prostate cancer. </li> <li class="seamTextUnorderedListItem">Some breast cancers contain androgen receptors. Laboratory studies suggest these tumors may respond to anti-androgen therapies.</li> <li class="seamTextUnorderedListItem">Targets or mutations: If your tumor is triple negative (ER-, PR-, HER2-), it must test positive for androgen receptors (AR)</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03650894' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipilimumab' target='_blank'>NCI drug dictionary: Ipilimumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nivolumab' target='_blank'>NCI drug dictionary: Nivolumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bicalutamide' target='_blank'>NCI drug dictionary: Bicalutamide</a> </li></ul>
See more
89

NEAREST SITE: 538 miles
Providence Cancer Institute
Portland, OR

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03602079

A166 for Advanced HER2 Positive and HER2 Low Expression Breast Cancer

A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of the experimental therapy A166.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 low expression breast cancer that has not responded to standard therapies    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A166, by IV </li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A166 is a type of drug called an antibody-drug conjugate (ADC).</li> <li class="seamTextUnorderedListItem">A166 combines chemotherapy with a HER2 targeted therapy, allowing it to deliver the chemotherapy directly to the cancer cells. </li> <li class="seamTextUnorderedListItem">HER2 low expression is defined as IHC 1+ or IHC 2+/ISH-</li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03602079' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795827' target='_blank'>NCI Drug Dictionary: A166</a> </li></ul>
See more
90

NEAREST SITE: 538 miles
Providence Portland Medical Center ( Site 0001)
Portland, OR

VISITS: 1 visit every 3 weeks, ongoing

PHASE: I-II

NCT ID: NCT04521621

Experimental Immunotherapy V937 and Pembrolizumab for Advanced Breast Cancer

A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors Scientific Title

Purpose
To study the anti-cancer activity, safety and effects (good and bad) of giving the targeted immunotherapy V937 (CAVATAK®) along with the PD-1 inhibitor pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer with either triple negative (ER-, PR-, HER2-) breast cancer and a tumor that can be reached for injection, or a metastatic tumor in your liver.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">V937 (CAVATAK®), injected directly into your tumor, 8 times over 6.5 months</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">V937 (CAVATAK®) is an oncolytic virus--this means it targets and kills cancer cells. It may directly kill cancer cells and stimulate your immune system to go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">V937 is injected directly into the tumor.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of immunotherapy called a PD-1 inhibitor. It gets the immune system to go after cancer cells.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is approved to treat only certain types of breast cancer, and its use in this trial is considered experimental.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04521621' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.viralytics.com/our-pipeline/cavatak/cavataktm/' target='_blank'>Viralytics Drug Information Page: CAVATAK® (V937)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/coxsackievirus-v937' target='_blank'>NCI Drug Dictionary: V937 (Coxsackievirus A21)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/breast-cancer-immunotherapy-clinical-trials/' target='_blank'>Metastatic Trial Talk: Immunotherapy & Metastatic Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.google.com/search?q=keytruda&oq=keytruda&aqs=chrome..69i57j0i433l2j0l5.1621j0j7&sourceid=chrome&ie=UTF-8' target='_blank'>Merk Oncology Drug Information Page: Keytruda® (Pembrolizumab</a> </li></ul>
See more
91

NEAREST SITE: 538 miles
Providence Portland Medical Center
Portland, OR

VISITS: 1 visit every 2 weeks, ongoing

PHASE: I

NCT ID: NCT04440943

Immunotherapy CDX-527 for Advanced Breast Cancer

A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies Scientific Title

Purpose
To study the safety, effects (good and bad), and anti-cancer activity of the experimental immunotherapy CDX-527.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have already received standard of care therapies.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDX-527, by IV, every 2 weeks, ongonig</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDX-527 is a drug that has two functions: it bocks PD-1 and also targets CD27. This may activate the immune response more than targeting either PD-1 or CD27 alone. </li> <li class="seamTextUnorderedListItem">CDX-527 is an experimental immunotherapy. This means it is only available in clinical trials.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04440943' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://pubmed.ncbi.nlm.nih.gov/32451681/' target='_blank'>Journal Article Abstract: Development of CDX-527, A Bispecific Antibody Combining PD-1 Clockade and CD27 Costimulation for Cancer Immunotherapy</a> </li></ul>
See more
92

NEAREST SITE: 538 miles
Providence Portland Medical Center
Portland, OR

VISITS: 10 visits over the first 2 months, then monthly visits, ongoing

PHASE: I

NCT ID: NCT03329950

A Study of CDX-1140 as Monotherapy or in Combination in Pati...

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies Scientific Title

Purpose
To study the safety, effects (good and bad) and best dose of the experimental cancer drug CDX-1140 when it is used alone or in combination with CDX-301, which is also an experimental cancer drug.
Who is this for?
People with locally advanced (stage III) or metastatic (stage IV) breast cancer and have no other standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDX-1140 by IV, every 4 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDX-1140 by IV, every 4 weeks</li> <li class="seamTextUnorderedListItem">CDX-301 by injection, daily for 5 days per month, for the first 2 months</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A pre-treatment and on-treatment biopsy may be required</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CDX-1140 targets a protein called CD40, which is found on cancer cells. </li> <li class="seamTextUnorderedListItem">CDX-301 is a new type of tyrosine-kinase inhibitor. It is also a targeted therapy. </li> <li class="seamTextUnorderedListItem">This study is enrolling patients with other types of solid tumors.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03329950' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/793440' target='_blank'>NCI Dictionary: CDX-1140</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-flt3-ligand' target='_blank'>NCI Dictionary: CDX-301</a> </li></ul>
See more
93

NEAREST SITE: 602 miles
Huntsman Cancer Institute
Salt Lake City, UT

VISITS: 1 visit

PHASE: II

NCT ID: NCT04252859

Using a PET/CT Scan to Find Lobular Breast Cancer Cells Before Surgery for Stage I-IV Lobular Breast Cancer

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma Scientific Title

Purpose
To study whether a PET/CT scan using a (18F) FES tracer is more effective at finding lobular breast cancer cells than the standard of care.
Who is this for?
People diagnosed with stage I, stage II or stage III lobular breast cancer within the last 3 months and who have not yet had surgery and people with stage IV (metastatic) lobular breast cancer diagnosed within the last 3 months    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan using (18F) FES tracer, 1 time</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer. A tracer looks for and attaches to cancer cells.</li> <li class="seamTextUnorderedListItem">Lobular breast cancer is a subtype of breast cancer. It is estimated that 10 to 15 percent of all breast cancers are lobular. </li> <li class="seamTextUnorderedListItem">Standard of care PET/CT scans that use a FDG tracer generally do not find lobular breast cancer tumors as well as they find ductal breast cancer tumors and PET/CT scans are not usually given to people with stage I-II lobular breast cancer. </li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called (18F)Fluoroestradiol (FES). Researchers believe this tracer is better at locating and attaching to lobular cancer cells than the standard of care tracer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04252859' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://lobularbreastcancer.org/imagingilc/' target='_blank'>Lobular Breast Cancer Alliance: Imaging and Lobular Breast Cancer</a> </li></ul>
See more
94

NEAREST SITE: 602 miles
Huntsman Cancer Institute/University of Utah
Salt Lake City, UT

VISITS: 1 visit

PHASE: II

NCT ID: NCT02398773

Predicting Which Tumors in People With Newly Diagnosed Metastatic ER+ Breast Cancer Will Respond to Hormone Therapy

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer (EAI142) Scientific Title

Purpose
To see if FES-PET/CT scans can predict how ER+ breast cancer will respond to anti-hormone therapy.
Who is this for?
People with newly diagnosed metastatic (stage IV) breast cancer who have not yet received hormone therapy for metastatic disease and who have at least one tumor that is estrogen receptor positive (ER+).    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will undergo the following up to 30 days before starting standard hormone therapy: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FES tracer, by IV over 2 minutes</li> <li class="seamTextUnorderedListItem">followed by PET/CT imaging</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">May undergo a second FES-PET/CT at least 24 hours and no later than 10 days after the initial study</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tracers are chemicals that are used to find cancer cells in the body. </li> <li class="seamTextUnorderedListItem">This imaging trial will use the tracer fluoroestradiol (FES)--a tracer that finds estrogen receptors in breast cancer tumors. </li> <li class="seamTextUnorderedListItem">Giving an FES tracer before a PET/CT scan may help doctors find ER+ breast cancer cells that have spread to other parts of the body (metastasized).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02398773' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayo.edu/research/clinical-trials/cls-20347030' target='_blank'>Mayo Clinic Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info.cfm?pg=pet' target='_blank'>RadiologyInfo.org: Positron Emission Tomography - Computed Tomography (PET/CT)</a> </li><li class='seamTextUnorderedListItem'><a href='http://clincancerres.aacrjournals.org/content/23/2/407' target='_blank'>AACR: Estrogen Receptor Binding and Glycolytic Activity Predict Progression-Free Survival on Endocrine Therapy</a> </li></ul>
See more
95

NEAREST SITE: 602 miles
University of Utah, Huntsman Cancer Institute
Salt Lake City, UT

VISITS: 1 visit every 2 weeks, ongoing

PHASE: I-II

NCT ID: NCT03964532

Talazoparib and Avelumab for Advanced Breast Cancer (TALAVE)

TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Scientific Title

Purpose
To study the safety and effects (good and bad) of talazoparib (Talzenna®) when it is used along with avelumab (Bavencio®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have not already received a PARP inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily</li> <li class="seamTextUnorderedListItem">Avelumab (Bavencio®), by IV, every 2 weeks, starting 1 month after Talazoparib</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Talzenna is a type of targeted therapy called a PARP inhibitor. It is approved to treat patients with an inherited BRCA mutation who have advanced HER2-negative breast cancer. </li> <li class="seamTextUnorderedListItem">Bavencio is a type of immunotherapy called a PD-L1 inhibitor. It is approved to treat certain types of lung cancer. Its use in breast cancer is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03964532' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer' target='_blank'>FDA: FDA approves talazoparib to treat some advanced breast cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.practiceupdate.com/content/avelumab-is-clinically-active-and-safe-in-advancedmetastatic-breast-cancer/60403' target='_blank'>PracticeUpdate: Avelumab Is Clinically Active and Safe in Advanced/Metastatic Breast Cancer</a> </li></ul>
See more
96

NEAREST SITE: 602 miles
Research Site
Salt Lake City, UT

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03616587

AZD9833 With or Without Palbociclib in ER Positive and HER2 Negative Advanced Breast Cancer

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination With Palbociclib in Women With ER Positive, HER2 Negative Advanced Breast Cancer Scientific Title

Purpose
To evaluate the safety and effects (good and bad) of AZD9833 alone or in combination with palbociclib (Ibrance®).
Who is this for?
Women with ER positive and HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer that did not respond to standard therapies and has not been treated with more than two different chemotherapy regimens.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD9833</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD9833 </li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®)</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">AZD9833 is an experimental drug that targets the estrogen receptor and is being developed to treat ER positive, HER2 negative breast cancer. </li> <li class="seamTextUnorderedListItem">Ibrance is a targeted drug used to treat metastatic breast cancer. </li> <li class="seamTextUnorderedListItem">If you are premenopausal, you will also receive a drug that will put you in temporary menopause.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03616587' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancercare.org.uk/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/targeted-therapy/palbociclib-ibrance' target='_blank'>BreastCancerResearchUK: Palbociclib</a> </li></ul>
See more
97

NEAREST SITE: 650 miles
Mayo Clinic - AZ
Phoenix, AZ

VISITS: 4 visits the first month, then 1 visit a month, ongoing

PHASE: II

NCT ID: NCT04024436

TAS-120 (Futibatinib) for Advanced HER2 Negative Breast Cancer with FGFR Amplification

A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications Scientific Title

Purpose
To study the safety and anti-cancer activity of the FGFR inhibitor TAS-120 (futibatinib).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer that tests positive for certain FGFR gene amplifications. You must have already received at least one treatment for advanced disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups depending on the hormone status of your cancer: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Hormone negative</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAS-120 (futibatinib), by mouth, daily, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Hormone positive</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAS-120 (futibatinib), by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, monthly, ongoing</li> <li class="seamTextUnorderedListItem">Goserelin (Zoladex®), by injection, monthly, ongoing ( only if you are premenopausal)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAS-120 (futibatinib) is a type of targeted therapy called a kinase inhibitor. </li> <li class="seamTextUnorderedListItem">It is designed to block the FGFR (fibroblast growth factor receptor) protein.</li> <li class="seamTextUnorderedListItem">Targets or mutations: FGFR</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04024436' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fgfr-inhibitor-tas-120' target='_blank'>NCI Drug Dictionary: Futibatinib</a> </li><li class='seamTextUnorderedListItem'><a href='http://targetedcancercare.massgeneral.org/My-Trial-Guide/Diseases/Breast-Cancer/FGFR-1,-2,-3-and-4.aspx' target='_blank'>Massachusetts General Hospital Cancer Canter: Breast Cancer, FGFR</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.faslodex.com/home.html' target='_blank'>AstraZeneca Drug Information Page: (Faslodex®) Fulvestrant</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-breast-cancer-treatment/hormone-therapy/goserelin-zoladex' target='_blank'>Breast Cancer Now: Goserelin</a> </li></ul>
See more
98

NEAREST SITE: 650 miles
Mayo Clinic
Phoenix, AZ

VISITS: Number of visits unavailable, ongoing

PHASE: I

NCT ID: NCT04521686

Experimental Targeted Therapy LY3410738 for Advanced Breast Cancer with a Certain Mutation

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 Mutations Scientific Title

Purpose
To study the safety, anti-cancer activity and side effects of the experimental targeted therapy LY3410738.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer whose tumor tests positive for an IDH1 R132 mutation and who have no standard treatment options available. Your tumor will be tested for this mutation.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3410738, by mouth, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LY3410738 is an experimental type of targeted therapy called a IDH1 inhibitor.</li> <li class="seamTextUnorderedListItem">Target or mutation: IDH1 R132</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04521686' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.loxooncology.com/pipeline' target='_blank'>Loxo Oncology Drug Information Page: LY3410738</a> </li></ul>
See more
99

NEAREST SITE: 660 miles
Mayo Clinic - Arizona
Scottsdale, AZ

VISITS: 1 visit every 3 weeks

PHASE: I-II

NCT ID: NCT04246671

Experimental Vaccine for Advanced HER2 Positive Breast Cancer

Phase 1/2 Expansion Cohorts Trial of Intravenous Administration of TAEK-VAC-HerBy Vaccine Alone and in Combination With HER2- and PD-1/PD-L1 Antibodies in Patients With Advanced HER2-expressing Cancer Scientific Title

Purpose
To study the safety, anti-cancer activity and effects (good and bad) of giving an experimental vaccine called TAEK-VAC-HerBy alone or in combination with other therapies.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have already received at least one therapy for advanced disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vaccine (TAEK-VAC-HerBy), by IV, every 3 weeks, 3 times</li> </ul> <p class="seamTextPara"> With or without one or more of the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV</li> <li class="seamTextUnorderedListItem">T-DM1 (Kadcyla®), by IV</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV</li> <li class="seamTextUnorderedListItem">a PD-1/PD-L1 inhibitor, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TAEK-VAC-HerBy is the experimental vaccine used in this trial. Researchers believe it may stimulate the immune system to go after HER2 positive cancer cells.</li> <li class="seamTextUnorderedListItem">Other therapies you may receive during this trial include: trastuzumab (Herceptin®), T-DM1 (Kadcyla®), pertuzumab (Perjeta®), and a PD-1/PD-L1 inhibitor.</li> <li class="seamTextUnorderedListItem">Trastuzumab and pertuzumab are anti-HER2 targeted therapies commonly used to treat advanced HER2 positive breast cancer.</li> <li class="seamTextUnorderedListItem">T-DM1 is an antibody-drug conjugate (ADC). It uses the HER2-targeted therapy trastuzumab to deliver the chemotherapy DM1 directly to cancer cells.</li> <li class="seamTextUnorderedListItem">PD-1/PD-L1 inhibitors are a type of immunotherapy. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancers.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04246671' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/taek-vac-herby-vaccine?redirect=true' target='_blank'>NCI Drug Dictionary: TAEK-VAC-HerBy Vaccine</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/inside-clinical-trials/breast-cancer-treatment-vaccines/' target='_blank'>Metastatic Trial Talk: Breast Cancer Treatment Vaccines</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/her2-positive-breast-cancer-research-update/' target='_blank'>Metastatic Trial Talk: HER2 Positive Metastatic Breast Cancer Research Update</a> </li></ul>
See more
100

NEAREST SITE: 660 miles
Mayo Clinic in Arizona
Scottsdale, AZ

VISITS: 1 visit weekly, ongoing

PHASE: II

NCT ID: NCT03179904

TVB-2640 with Taxol and Herceptin for Advanced, HER2 Positive Breast Cancer

Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Paclitaxel and Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab and Taxane-Based Therapy Scientific Title

Purpose
To look at the safety and effects (good and bad) of using a new targeted therapy along with both chemotherapy and a HER2-targeted therapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV), HER2 positive (HER2+) breast cancer. Your cancer must have progressed after receiving trastuzumab (Herceptin®) and pertuzumab (Perjeta®) and you must have also already received a taxane-based chemotherapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TVB-2640, by mouth, daily, ongoing </li> <li class="seamTextUnorderedListItem">Paclitaxel (Taxol®), by IV, weekly, ongoing </li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, weekly, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The new targeted therapy used in this study is TVB-2640. It stops cancer cells from growing by targeting a protein called FASN. </li> <li class="seamTextUnorderedListItem">The chemotherapy drug used in this study is paclitaxel (Taxol®). </li> <li class="seamTextUnorderedListItem">The HER2-targeted drug is trastuzumab (Herceptin®).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03179904' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.3vbio.com' target='_blank'>Drug Company Information Page: TVB-2640</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fasn-inhibitor-tvb-2640' target='_blank'>NCI Drug Dictionary: TVB-2640</a> </li></ul>
See more
101

NEAREST SITE: 671 miles
Site 2
Gilbert, AZ

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04514159

Experimental Anti-Estrogen ZN-C5 and Abemaciclib for Advanced, ER+, HER2- Breast Cancer

A Phase 1b Study of ZN-c5 in Combination With Abemaciclib in Patients With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer Scientific Title

Purpose
To study the safety, side effects and anti-cancer activity of giving the experimental anti-estrogen therapy ZN-C5 in combination with the CDK 4/6 inhibitor abemaciclib (Verzenio®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have not already received a CDK 4/6 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will recieve the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®), by mouth, daily (twice a day), ongoing </li> <li class="seamTextUnorderedListItem">ZN-C5, by mouth, daily (once or twice a day), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-C5 is a type of anti-estrogen therapy called a SERD (selective estrogen receptor degrader).</li> <li class="seamTextUnorderedListItem">Abemaciclib (Verzenio®) is a CDK 4/6 inhibitor that is commonly used to treat metastatic, hormone positive (ER+ and/or PR+) breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04514159' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://zentalis.com/#pipeline' target='_blank'>Zentalis Pharmaceuticals Drug Information Page: ZN-C5</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader' target='_blank'>Wikipedia: SERD</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ajmc.com/view/in-drug-pricing-pbms-called-the-arsonist-and-the-firefighter-in-one-' target='_blank'>American Journal of Managed Care (video): Dr Joanne Mortimer Discusses Novel Oral SERD ZN-c5 in ER-Positive Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/verzenio' target='_blank'>Breastcancer.org: Abemaciclib</a> </li></ul>
See more
102

NEAREST SITE: 682 miles
Fred Hutchinson Cancer Research Center
Seattle, WA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04020575

CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for MUC 1*

Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*) Scientific Title

Purpose
To look at the safety, best dose and effects of an experimental CAR T-cell immunotherapy that targets cancer cells that test positive for MUC1*, a special type of the MUC1 protein.
Who is this for?
People with metastatic (stage IV) breast cancer that tests positive for MUC1 and who have already received at least one standard therapy.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw to collect white blood cells to make your personalized CAR T-cell therapy (leukapheresis)</li> <li class="seamTextUnorderedListItem">Chemotherapy to deplete your lymph cells</li> <li class="seamTextUnorderedListItem">huMNC2-CAR44 CAR T-cells, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule. Hospital stay may be required.</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAR T-cell therapy is a personalized immunotherapy made from your white blood cells. </li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so that they can attack a specific protein. </li> <li class="seamTextUnorderedListItem">The CAR T-cells are then infused back into you while you are hospitalized </li> <li class="seamTextUnorderedListItem">The CAR T-cell therapy being used in this study trains the immune system to attack MUC1 on cancer cells.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04020575' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html' target='_blank'>MD Anderson Cancer Center: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/research/car-t-cells' target='_blank'>NCI: Car T-Cells</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.minervabio.com/clinical-trial-humnc2-car44-in-mbc/' target='_blank'>Minerva Biotechnologies: Study Page</a> </li></ul>
See more
103

NEAREST SITE: 682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

VISITS: 7 visits over 15 months

PHASE: I

NCT ID: NCT02157051

A Vaccine for Advanced, HER2 Negative Breast Cancer

A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients Scientific Title

Purpose
To study the effects (good and bad) and best dose of an experimental STEMVAC vaccine.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV), HER2 negative (HER2-) breast cancer who have no evidence of disease or metastasis to bone only.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">STEMVAC vaccine, by injection, every month for 3 months, and at 6 and 12 months</li> <li class="seamTextUnorderedListItem">Follow up visits during months 4 and 15</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Vaccines made from DNA from tumor cells may help the body build an effective immune response to the cancer. </li> <li class="seamTextUnorderedListItem">The STEMVAC is designed to target a protein on breast cancer stem cells that is resistant to chemotherapy.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02157051' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.historyofvaccines.org/content/articles/cancer-vaccines-and-immunotherapy' target='_blank'>The College of Physicians of Philadelphia: Cancer Vaccines and Immunotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='http://sharedresources.fredhutch.org/profile/disis-nora' target='_blank'>Lead Researcher: Dr. Nora Disis</a> </li><li class='seamTextUnorderedListItem'><a href='https://depts.washington.edu/tumorvac/clinical-trials/breast-cancer/protocol-137' target='_blank'>University of Washington Medicine Cancer Vaccine Institute: Study website</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2018/10/03/mbc-news-4/' target='_blank'>MetastaticTrialTalk.org: Immunotherapy & Metastatic Breast Cancer</a> </li></ul>
See more
104

NEAREST SITE: 682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle, WA

VISITS: 1 visit every 3 weeks

PHASE: I

NCT ID: NCT04120246

Alpha-TEA and Trastuzumab for Metastatic HER2 Positive Breast Cancer

A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer Scientific Title

Purpose
To study the best dose and effects (good and bad) of giving alpha-TEA in combination with trastuzumab (Herceptin®).
Who is this for?
People with metastatic (stage IV) HER2 positive (HER2+) breast cancer who have already received trastuzumab (Herceptin®), pertuzumab (Perjeta®), and trastuzumab emtansine/T-DM1 (Kadcyla®) for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpha-TEA, by mouth, daily (2 weeks on, 2 weeks off), ongoing</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">You will also receive your doctor's choice of hormone therapy if your tumor is hormone positive</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpha-TEA is a drug derived from vitamin E.</li> <li class="seamTextUnorderedListItem">Alpha-TEA may stimulate the immune system to fight cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is commonly used to treat people with metastatic HER2 positive breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04120246' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/alpha-tocopheryloxyacetic-acid' target='_blank'>NCI Drug Dictionary: Alpha-Tocopheryloxyacetic Acid (Alpha-TEA)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li></ul>
See more
105

NEAREST SITE: 682 miles
Fred Hutchinson Cancer Research Center
Seattle, WA

VISITS: At least 2 visits every 3 weeks

PHASE: I-II

NCT ID: NCT03678883

9-ING-41 Targeted Therapy With or Without Chemotherapy for Patients With Advanced Breast Cancer

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors Scientific Title

Purpose
To determine the safety and the effects (good and bad) of the investigational targeted therapy 9-ING-41 when it is used with or without chemotherapy.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no other standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to receive: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Experimental drug alone</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">9-ING-41, by IV, 2 times every 3 weeks </li> </ul> <p class="seamTextPara"> or </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Experimental drug plus chemo</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">9-ING-41, by IV, 2 times every 3 weeks</li> <li class="seamTextUnorderedListItem">Chemotherapy (one of the following: gemcitabine, doxorubicin, lomustine, carboplatin, nab-paclitaxel plus gemcitabine, or paclitaxel plus carboplatin)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The drug 9-ING-41 is a type of targeted therapy called a GSK-3β inhibitor. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03678883' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://clinicaltrials.ucsf.edu/trial/NCT03678883' target='_blank'>UCSF trial information</a> </li></ul>
See more
106

NEAREST SITE: 682 miles
Site 5
Seattle, WA

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04176757

ZN-C5 for Stage I, II, III, and IV ER+, HER2- Breast Cancer

A Phase 1 Open-Label, Multicenter Study to Evaluate Biomarkers for ZN-c5 in Subjects With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Scientific Title

Purpose
To determine the best dose of the investigational drug ZN-c5.
Who is this for?
People with stage I, stage II, stage III, or stage IV (metastatic) estrogen positive (ER+), HER2 negative (HER2-) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c5, by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c5 is a type of hormone therapy called a SERD (selective estrogen receptor degrader).</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04176757' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.zentalis.com/#pipeline' target='_blank'>Drug Company Information Page: ZN-C5</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader' target='_blank'>Wikipedia: Selective Estrogen Receptor Degrader (SERD)</a> </li></ul>
See more
107

NEAREST SITE: 682 miles
Investigational Site Number 8400001
Seattle, WA

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT03284957

SAR439859 with Ibrance in Postmenopausal Women with ER+, HER2- Advanced Breast Cancer

A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer Scientific Title

Purpose
To determine the best dose, safety and effects (good and bad) of SAR439859 when it is given alone or in combination with palbociclib (Ibrance®).
Who is this for?
Postmenopausal women with estrogen receptor positive, HER2 negative, advanced (some stage III) or metastatic (stage IV) breast cancer . You must have received prior treatment for advanced breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR439859, by mouth, daily, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR439859, by mouth, daily, ongoing</li> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SAR439859 is an experimental anti-estrogen drug. It is available only in clinical trials. </li> <li class="seamTextUnorderedListItem">Ibrance® is a targeted therapy that blocks the CDK4/6 protein. It is approved to treat postmenopausal women with ER+, HER2- metastatic breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03284957' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://cancerres.aacrjournals.org/content/77/4_Supplement/P3-04-05' target='_blank'>Cancer Research: SAR439859</a> </li></ul>
See more
108

NEAREST SITE: 752 miles
Site 0102
Tucson, AZ

VISITS: Number of visits unavailable

PHASE: I-II

NCT ID: NCT04158336

Targeted Therapy ZN-c3 Alone or with Talazoparib or Pembrolizumab in Advanced Breast Cancer

A Phase 1/2 Study of ZN-c3 as a Single Agent and in Combination With Talazoparib or Pembrolizumab in Patients With Solid Tumors Scientific Title

Purpose
To look at the safety and effects (good and bad) of the experimental targeted therapy ZN-c3 when it is used alone or with talazoparib (Talzenna®) or pembrolizumab (Keytruda®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 3 groups; </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c3, by mouth</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c3, by mouth</li> <li class="seamTextUnorderedListItem">Talazoparib (Talzenna®), by mouth, daily</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 3</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c3, by mouth</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ZN-c3 is tyrosine kinase inhibitor that blocks a protein called WEE1 that helps tumors grow. </li> <li class="seamTextUnorderedListItem">Talzenna® is a type of targeted therapy called a PARP inhibitor. It prevents the PARP protein from repairing damaged DNA in tumor cells. It is approved to treat advanced HER2-negative breast cancer in people with an inherited BRCA mutation. </li> <li class="seamTextUnorderedListItem">Keytruda® is an immunotherapy that targets the programmed cell death (PD-1) protein. Blocking this protein allows the body's immune system to attack cancer cells. It is approved to treat certain types of cancer. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: WEE1</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04158336' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor' target='_blank'>NCI Drug Dictionary: PARP Inhibitor</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.talzenna.com/?source=google&HBX_PK=s_talazoparib&skwid=43700039109817433' target='_blank'>Pfizer Oncology: Talzenna® (Talazoparib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://blog.dana-farber.org/insight/2019/05/the-science-of-pd-1-and-immunotherapy/' target='_blank'>Dana-Farber Cancer Institute: What is PD-1 and Immunotherapy?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology: Keytruda® (Pembrolizumab)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.businesswire.com/news/home/20191218005179/en/Zentalis-Pharmaceuticals-Announces-FDA-Clearance-IND-Oncology' target='_blank'>Drug Company Press Release: ZN-c3</a> </li></ul>
See more
109

NEAREST SITE: 941 miles
University of Colorado Hospital
Aurora, CO

VISITS: 1 visit every 2 or 3 weeks, ongoing

PHASE: I-II

NCT ID: NCT04108858

Copanlisib for Stage IV HER2 Positive Breast Cancer with a PIK3CA or PTEN Mutation

Phase Ib/II Trial of Copanlisib in Combination With Trastuzumab and Pertuzumab After Induction Treatment of HER2 Positive (HER2+) Metastatic Breast Cancer (MBC) With PIK3CA Mutation or PTEN Mutation Scientific Title

Purpose
To study the best dose, effects (good and bad), and anti-cancer activity of adding copanlisib (Aliqopa®) to the combination of trastuzumab (Herceptin®) and pertuzumab (Perjeta®).
Who is this for?
People with metastatic (stage IV) HER2 positive (HER2+) breast cancer that tests positive for a PIK3CA or PTEN mutation and who have already received chemotherapy for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Experimental</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Copanlisib (Aliqopa®), by IV, every week (2 weeks on, 1 week off), ongoing</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Standard of care</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Pertuzumab (Perjeta®), by IV, every 3 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Copanlisib (Aliqopa®) is a type of targeted therapy called a PI3K inhibitor. It is approved for use in lymphoma, but its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) and pertuzumab (Perjeta®) are targeted therapies routinely used to for HER2 positive breast cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PIK3CA (PI3K) and PTEN</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04108858' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.aliqopa-us.com/?utm_source=google&utm_medium=cpc&utm_campaign=Aliqopa_Branded_Patient_%3BS%3BPH%3BBR%3BONC%3BDTC%3BBR&utm_content=General&utm_term=copanlisib&matchtype=e&device=c&adposition=&loc=9008590&gclid=Cj0KCQjwjer4BRCZARIsABK4QeVEb_yjzH' target='_blank'>Bayer Drug Information Page: Aliqopa® (Copanlisib)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies' target='_blank'>Breastcancer.org: Targeted Therapies</a> </li></ul>
See more
110

NEAREST SITE: 941 miles
University of Colorado Denver
Aurora, CO

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT01503190

Immune System Response to Breast Cancer in Women Under Age 50

A Translational Study of the Interactions Between Prior Pregnancy and the Biologic Subtype of Breast Cancer in Defining the Cancer: Host Immunologic Interaction Scientific Title

Purpose
To determine how the immune system responds to different types of tumors or to tumors that develop during or after a pregnancy. Some of the breast cancer tissue collected in this study will be used to create models that develop and test new drug treatments.
Who is this for?
Women with any stage of breast cancer who are 50 years or younger    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> All participants will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tissue, blood and urine samples, if recently diagnosed</li> <li class="seamTextUnorderedListItem">Tissue donation only, if enrolled after treatment has begun or has ended</li></ul>
  • <p class="seamTextPara"> Researchers are interested in learning more about the role the immune system plays in cancer. </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study is looking specifically at the level of immune suppression seen in breast cancer that occurs in women under age 50.</li> </ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01503190' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.breastcancer.org/tips/immune/' target='_blank'>BreastCancer.org: Understanding Your Immune System</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.youngsurvival.org/' target='_blank'>Young Survival Coalition</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/MedicalOncology/faculty/Pages/VirginiaFBorges,MD.aspx' target='_blank'>Study PI: Virginia F. Borges, MD</a> </li></ul>
See more
111

NEAREST SITE: 947 miles
HealthONE Clinic Services Oncology-Hematology
Denver, CO

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04045496

A New Targeted Therapy (JAB-3312) for Advanced Breast and Other Cancers

A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients With Advanced Solid Tumors Scientific Title

Purpose
To study the safety, best dose, and effects (good and bad) of the experimental drug JAB-3312.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that was treated with standard therapies or who have no standard therapy options.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">JAB-3312, by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">JAB-3312 is a type of targeted therapy called a KRAS inhibitor. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04045496' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/799443' target='_blank'>NCI Drug Dictionary: JAB-3312</a> </li><li class='seamTextUnorderedListItem'><a href='http://en.jacobiopharma.com/news/97.html' target='_blank'>Drug Company Information Page: JAB-3312</a> </li></ul>
See more
112

NEAREST SITE: 948 miles
Sarah Cannon Research Institute at HealthONE
Denver, CO

VISITS: 1 visit a week, ongoing

PHASE: I-II

NCT ID: NCT04561362

Immunotherapy and BT8009 for Metastatic Breast Cancer that Expresses Nectin-4

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies Scientific Title

Purpose
To study the safety, anti-cancer activity, and effects (good and bad) of giving the experimental therapy BT8009 alone or in combination with the PD-1 inhibitor nivolumab (Opdivo®).
Who is this for?
People with metastatic (stage IV) breast cancer that expresses Nectin-4 and who have no standard treatment options available.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups and receive the following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BT8009, by IV, once a week, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BT8009, by IV, once a week, ongoing</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 2 weeks, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BT8009 is an experimental therapy that targets Nectin-4, a protein expressed in some breast cancer cells, and delivers a drug that can kill cancer cells.</li> <li class="seamTextUnorderedListItem">Nectin-4 is often expressed in triple negative (ER-, PR-, HER2-) breast cancer. </li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®) is a type of immunotherapy called a checkpoint inhibitor. It gets the immune system to go after cancer cells by blocking a protein called PD-1 (programmed cell death 1). It has been approved to treat certain types of cancer. Its use in breast cancer is considered experimental.</li> <li class="seamTextUnorderedListItem">Targets or mutations: Nectin-4</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04561362' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://investors.bicycletherapeutics.com/news-releases/news-release-details/bicycle-therapeutics-announces-first-patient-dosed-phase-iii-0' target='_blank'>Press Release: BT8009</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bicycletherapeutics.com/programs/' target='_blank'>Bicycle Therapeutics Drug Information Page: BT8009</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/nivolumab' target='_blank'>NCI Drug Dictionary: Nivolumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Nectin' target='_blank'>Wikipedia: Nectin</a> </li></ul>
See more
113

NEAREST SITE: 1175 miles
St. Catherine Hospital - Central Care Cancer Center
Garden City, KS

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT02595320

Comparing Two Different Doses of Capacitabine for Metastatic Breast Cancer

Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers Scientific Title

Purpose
To study the anti-cancer activity and side effects of giving capecitabine (Xeloda®) on two different schedules and with two different doses.
Who is this for?
Women with metastatic (stage IV) breast cancer who have not already received capecitabine (Xeloda®) for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: 1500 mg</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capacitabine (Xeloda®), by mouth, twice daily (1 week on, 1 week off), ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: 1250 mg</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capacitabine (Xeloda®), by mouth, twice daily (2 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Capecitabine (Xeloda®) is a chemotherapy used to treat metastatic breast cancer that has stopped responding to other chemotherapy drugs. </li> <li class="seamTextUnorderedListItem">Because it is an oral drug (taken by mouth), you can receive the chemotherapy at home. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of metastatic cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02595320' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://breastcancernow.org/information-support/facing-breast-cancer/going-through-treatment-breast-cancer/chemotherapy/capecitabine-xeloda' target='_blank'>Breast Cancer Now: Capecitabine</a> </li></ul>
See more
114

NEAREST SITE: 1251 miles
Hays Medical Center Dreiling-Schmidt Cancer Institute
Hays, KS

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02302742

A Registry for People with Triple Negative or ER-Low, HER2- Breast Cancer or an Inherited BRCA1/2 or Certain Other Mutations

PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations (PROGECT) Scientific Title

Purpose
To learn more about the relationship between genetic mutations and cancer outcomes.
Who is this for?
People with inherited BRCA1/2 mutations or certain other genetic mutations (see list below) and people with stage I, stage II, stage III, or stage IV triple negative (ER-, PR-, HER2-) or ER-Low (1%-10% ER) breast cancer.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> This is a data collection (registry) study. You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">1 blood test</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast cancer that tests positive for 1%-10% estrogen receptors is called ER-Low.</li> <li class="seamTextUnorderedListItem">This trial is enrolling people with triple negative as well as ER-Low breast cancer.</li> <li class="seamTextUnorderedListItem">Studies have found a relationship between triple negative breast cancer and inherited BRCA1 and BRCA2 mutations. </li> <li class="seamTextUnorderedListItem">Targets or mutations: BRCA1, BRCA2, PTEN, P53, and PALB2</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02302742' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.cancer.net/cancer-types/hereditary-breast-and-ovarian-cancer' target='_blank'>ASCO: Hereditary Breast and Ovarian Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='http://ww5.komen.org/BreastCancer/InheritedGeneticMutations.html' target='_blank'>Susan G. Komen: Inherited Gene Expressions</a> </li><li class='seamTextUnorderedListItem'><a href='https://tnbcfoundation.org' target='_blank'>Triple Negative Breast Cancer Foundation</a> </li><li class='seamTextUnorderedListItem'><a href='https://ghr.nlm.nih.gov/condition/breast-cancer' target='_blank'>NIH Genetics Home Reference: Breast Cancer</a> </li></ul>
See more
115

NEAREST SITE: 1382 miles
Mercy Hospital Oklahoma City
Oklahoma City, OK

VISITS: 1 visit every week (2 weeks on, 1 week off), ongoing

PHASE: II

NCT ID: NCT04647916

Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases Scientific Title

Purpose
To study the anti-cancer activity, safety and side effects of giving the antibody-drug conjugate sacituzumab govitecan (Trodelvy®) to treat brain metastases (breast cancer that has spread to the brain).
Who is this for?
People with metastatic (stage IV) HER2 negative (HER2-) breast cancer that has spread to the brain.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®), by IV, every week (2 weeks on, 1 week off), ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Sacituzumab govitecan (Trodelvy®) is an antibody-drug conjugate (ADC). This means it uses an antibody that targets cancer cells to deliver a chemotherapy drug directly to these cells.</li> <li class="seamTextUnorderedListItem">The antibody in this drug targets TROP2 proteins. It delivers the chemotherapy irinotecan. Irinotecan is approved for use in many other types of cancer.</li> <li class="seamTextUnorderedListItem">Sacituzumab govitecan is approved for use in people with metastatic triple negative breast cancer who have already received at least two other therapies for metastatic disease, but its use in this trial is considered experimental.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04647916' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-sacituzumab-govitecan-triple-negative-breast-cancer' target='_blank'>NCI Cancer Currents Blog: Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.targetedonc.com/view/sacituzumab-govitecan-shows-pfs-benefit-for-patients-with-mtnbc-and-brain-metastases' target='_blank'>Targeted Oncology: Sacituzumab Govitecan Shows PFS Benefit for Patients With mTNBC and Brain Metastases</a> </li></ul>
See more
116

NEAREST SITE: 1387 miles
Stephenson Cancer Center
Oklahoma City, OK

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT04247126

Targeted Therapy SY 5609 in Advanced, Hormone Positive, HER2 Negative Breast Cancer

A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors Scientific Title

Purpose
To study the best dose, safety, and anti-cancer activity of the experimental targeted therapy SY 5609.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV), hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer whose disease progressed while receiving a CDK 4/6 inhibitor and an anti-hormone therapy. If you are a woman, you must also be postmenopausal.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SY-5609, by mouth</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">SY 5609 is an experimental type of targeted therapy called a CDK 7 inhibitor (cyclin-dependent kinase 7 inhibitor).</li> <li class="seamTextUnorderedListItem">Researchers believe that SY 5609 may be effective in treating tumors that have not responded to a CDK 4/6 inhibitor.</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®) is a hormone therapy approved to treat postmenopausal women with advanced breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04247126' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.syros.com/programs/sy-5609' target='_blank'>Syros Pharmaceuticals Drug Information Page: SY 5609</a> </li><li class='seamTextUnorderedListItem'><a href='http://chemocare.com/chemotherapy/drug-info/fulvestrant.aspx' target='_blank'>Chemocare: Fulvestrant (Faslodex®)</a> </li></ul>
See more
117

NEAREST SITE: 1387 miles
University of Oklahoma Health Sciences Center
Oklahoma City, OK

VISITS: 2 visits over 4 months

PHASE: II

NCT ID: NCT04316117

Using PET/CT Scans to See How Breast Cancer That Has Spread to the Bones is Responding to Therapy

FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE Scientific Title

Purpose
To study if PET/CT scans with a FDG tracer find tumors missed by standard of care imaging and can see how breast cancer tumors that have spread to the bones are responding to therapy.
Who is this for?
People with stage IV (metastatic) breast cancer that has spread to their bones and who have not received more than 3 chemotherapies for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FDG tracer, by IV, followed by PET/CT scan, 2 times (1 scan before treatment, 1 scan 3 months after starting treatment)</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called FDG (fluorodeoxyglucose). </li> <li class="seamTextUnorderedListItem">FDG produces color-coded images that show normal and cancerous tissue.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04316117' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/clinical-trials/ea1183-educational-materials' target='_blank'>ECOG-ACRIN Study Information Page: FEATURE</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET-CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.docpanel.com/blog/post/understanding-your-fdg-pet-scan' target='_blank'>Docpanel: Understanding Your FDG PET Scan</a> </li></ul>
See more
118

NEAREST SITE: 1398 miles
Avera Cancer Institute
Sioux Falls, SD

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT03154281

PARP Inhibitor Niraparib With Everolimus in Advanced HER2 Negative Breast Cancer

A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast Cancer Scientific Title

Purpose
To assess the safety, effects (good and bad) and best dose of the PARP inhibitor niraparib (Zejula®) when used with everolimus (Afinitor®).
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer who have no standard treatment options available and who have not already received a PARP inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Niraparib (Zejula®), by mouth, daily </li> <li class="seamTextUnorderedListItem">Everolimus (Afinitor®), by mouth, daily or every other day</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Zejula is at type of targeted therapy called a PARP inhibitor. These drugs block poly (ADP-ribose) polymerase. </li> <li class="seamTextUnorderedListItem">This enzyme helps cancer cells grow by repairing their DNA. It is approved to treat women with certain types of reproductive cancers. </li> <li class="seamTextUnorderedListItem">Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Afinitor is a type of targeted drug called an mTOR inhibitor. It is used to treat advanced hormone receptor-positive, HER2-negative breast cancer. </li> <li class="seamTextUnorderedListItem">This study also is recruiting patients with ovarian cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03154281' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/resources-information-approved-drugs/everolimus-afinitor' target='_blank'>FDA Approval: Everolimus (Afinitor®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/resources-information-approved-drugs/niraparib-zejula' target='_blank'>FDA Approval: Niraparib (Zejula®)</a> </li></ul>
See more
119

NEAREST SITE: 1414 miles
Nebraska Cancer Center Oncology Hematology West P.C.
Omaha, NE

VISITS: 1 visit every 3 weeks, ongoing

PHASE: I

NCT ID: NCT04485013

Experimental Immunotherapy for Advanced Breast Cancer that Expresses HLA-G

A First-in-human, Phase 1 Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects With Advanced Solid Tumors Scientific Title

Purpose
To study the safety, side effects and anti-tumor activity of the experimental immunotherapy TTX-080.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer whose tumor expresses HLA-G.    Full eligibility criteria
Contact research site